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Current pharmacokinetic-pharmacodynamic models describing changes to the 
haemodynamic system often do not include necessary feedback mechanisms. These models 
often provide adequate empirical description of data but may fail to adequately extrapolate to 
additional scenarios. This study aimed to develop a minimal model to describe the short-term 
changes of haemodynamics that can be used as the basis for future model development. The 
model was used to describe the haemodynamic effects of sodium nitroprusside (SNP) in 
adolescents undergoing surgery. 
A minimal haemodynamic model was developed to describe the influence of drugs on 
blood pressure components. The model structure was defined based on known mechanisms and 
previously published models. The model parameters were calibrated to describe (without 
estimation) the heamodynamics of two antihypertensive drugs with data extracted from the 
literature. Structural identifiability analysis was done using various combinations of the 
observed variables. The model was applied to clinical data from patients receiving SNP 
infusion. The model was extended to accommodate the postulated mechanism of action of SNP 
in the literature. 
The proposed model structure included mean arterial pressure (MAP), heart rate (HR), 
and stroke volume and was composed of four states described by differential equations. Model 
evaluation showed flexibility in describing haemodyanmics at different target perturbations. 
Overlay plots of model predictions and literature data showed a good description without data 
fitting. The structural identifiability analysis revealed all model parameters and initial 
conditions were identifiable only when HR, MAP, and cardiac output were measured together. 
In addition, model evaluation using SNP data suggested its mechanistic plausibility and the 
flexibility to describe various response patterns elicited by SNP 
A minimal model of the haemodynamic system was developed and evaluated. The 
model accounted for short-term haemodynamic feedback processes. We propose that this 
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Aims and structure of the thesis  
The overarching aim of this thesis was to apply pharmacometric methods to 
quantitatively describe and predict the cardiovascular haemodynamics in humans and to show 
the applications of a haemodynamic model to clinical data. 
The specific aims were to: 
I. Develop a semi-mechanistic model to describe the haemodynamics of the 
cardiovascular system in humans (chapter 2). 
II. Extend the developed model to model the haemodynamic effects of sodium 
nitroprusside in adolescents undergoing surgery (chapter 3). 
The thesis has been divided into four chapters: 
- Chapter 1  
This provides an introduction to the thesis. This chapter has four sections 
I. Section 1.1 includes a review of the physiology of the cardiovascular 
haemodynamics in humans 
II. Section 1.2 includes a review of the current state of knowledge of published 
models that provided a quantitative description of the haemodynamics of 
the cardiovascular system.  
III. Section 1.3 includes a review of the pharmacology of sodium nitroprusside 
and its clinical uses. 
IV. Section 1.4 includes a review of the pharmacometric methods applied in the 
current thesis 
- Chapter 2  
This focuses on the development of a minimal model to describe haemodynamics 
in humans. It also covers model evaluation using published clinical data and an analysis 
of model identifiability. 
- Chapter 3 
In this chapter, the developed model in chapter 2 is extended to model clinical data 
of nitroprusside when used in adolescents. The chapter includes a description of the 
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- Chapter 4 
This chapter provides a discussion of the results of chapters 2 and 3 in addition to 
concluding remarks.  
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1.1 Cardiovascular haemodynamics 
Cardiovascular haemodynamics is the study of blood flow through the cardiovascular 
system (CVS) and the factors governing it. These factors include blood pressure (BP) and the 
resistance to this flow (Klabunde, 2012).  
1.1.1 Blood pressure (BP) 
Blood pressure (BP) is the tension within the blood vessel wall, resulting from blood 
flow through the lumen within the major arterial system of the body (Walker HK et al., 1990, 
Adelmann, 2011). BP is measured in millimetres of mercury (mmHg). 
Blood flows throughout the CVS by means of the heart pumping force and pressure 
differences throughout the vasculature.  Hence, BP is not the same in all types of blood vessels; 
otherwise the blood will not flow. These differences can be mainly explained by the different 
compliance profiles of different blood vessels (Costanzo, 2018). An illustration of the 
differences in BP throughout different blood vessels is represented in Figure 1 . 
 Each cycle of pulsation of arterial BP during systole and diastole coincides with one 
cardiac cycle.  The arterial BP is usually described by the systolic blood pressure (SBP) and 
diastolic blood pressure (DBP).  
Figure 1 Blood pressure profile in the vasculature. Black line represents the mean 
arterial pressure, green line represents the systolic and diastolic blood pressure  
(Costanzo, 2018) 
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1.1.1.1 Systolic blood pressure (SBP) 
  It represents the maximum aortic blood pressure, which is achieved during cardiac 
contraction due to the pressure exerted on the vascular wall by the ejected stroke volume (SV). 
1.1.1.2 Diastolic blood pressure (DBP) 
  It represents the lowest aortic blood pressure achieved after ventricular contraction 
when the cardiac chambers are filling. It provides the driving pressure for continuous blood 
flow to the peripheral tissues as the ventricles are refilled with blood for the next contraction 
(Cheng and Jusof, 2018, DiPiro, 2011). 
1.1.1.3 Mean arterial pressure (MAP) 
It represents the average arterial pressure throughout the cardiac cycle of contraction 
and reflect the degree of organ perfusion. It is worth noting that the mean arterial pressure 
(MAP) is not the BP halfway between the diastolic and systolic pressures because the duration 
of diastole is longer than the duration of systole in a normal cardiac cycle (Sparks and Rooke, 
1987). 
During a cardiac cycle, two thirds of the time is spent in diastole and one third in 
systole. Hence, the value for the mean pressure (geometric mean) is less than the arithmetic 
average of the systolic and diastolic pressures (Figure 2). That is why at normal resting heart 









Alternatively, it can be expressed as,  
𝑀𝐴𝑃 ≅ 𝐷𝐵𝑃 +
1
3




where PP is the pulse pressure. 
At high heart rates (HR), MAP is more closely approximated by the arithmetic mean 
of SBP and DBP as the aortic pulse wave becomes shorter where the duration of diastole 
shortens more than does systole. Different formulas have been developed to account for HR 
changes for MAP calculation; 
𝑀𝐴𝑃 ≅ 𝐷𝐵𝑃 + 0.01 ⋅ exp (4.14 −
40.74
𝐻𝑅
) ⋅ 𝑃𝑃 (Moran et al., 1995) 
Chapter 1: Introduction 
 
4 | P a g e  
 
𝑀𝐴𝑃 ≅ 𝐷𝐵𝑃 + (0.33 + 0.0012 ⋅ 𝐻𝑅) ⋅ 𝑃𝑃 (Razminia et al., 2004) 
To determine MAP with absolute accuracy, MAP can be measured using an 
indwelling arterial catheter. However, in normal clinical practice, SBP and DBP are more 
commonly measured, rather than MAP, due to the invasiveness of the used technique 
(Klabunde, 2012). 
 
Figure 2 Aortic pulse wave during one cardiac cycle (Klabunde, 2012) 
1.1.1.4 Pulse pressure  
The pulse pressure (PP) reflects the pulsatile component of BP estimated by the 
difference between SBP and DBP. PP provides a better prognostic sensitivity in 
cardiovascular risk stratification and arterial stiffness at older age relative to MAP, which 
could show a slight change, keeping it within the normal range (Selvaraj et al., 2016). For 
instance, in a normal individual with BP 120/80 mmHg, the PP will be 40 mmHg, and MAP 
equal to 93 mmHg, while in a patient with arterial stiffness having BP 140/65 mmHg, PP is 
increased to 75 mmHg, whereas MAP will be 90 mmHg (Franklin and Wong, 2016).  
PP can be used as an indicator of stroke volume (SV), when other factors are constant, 





, where C: vascular compliance, ΔV: the change in volume, ΔP: the change in pressure  
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Assuming that arterial compliance is constant in healthy adult, the change in arterial 
pressure, which is represented by PP, would depend on the change of blood volume in the 
artery at any moment in time, which is reflected by SV (Costanzo, 2018). Factors affecting 
PP are summarised in Figure 3.  
 
 
However, it is important to point out that although there is a strong correlation 
between PP and SV, it is not a linear relationship (Soltesz, 2018). Bighamian et al. reported 
that the relative change in arterial pulse pressure due to a left ventricular blood volume 
perturbation was consistently smaller than the corresponding relative change in SV, due to 
the nonlinear left ventricular pressure-volume relation during diastole. This in turn reduces 
the sensitivity of arterial PP to perturbations in the left ventricular blood volume. Therefore, 
arterial PP must be used with care when used as a surrogate for SV (Bighamian and Hahn, 
2014). 
Figure 3 Factors affecting aortic pulse pressure. (Klabunde, 2012) 
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1.1.2 Vascular compliance 
Vascular compliance describes the volume of blood the vessel can hold at a given 
pressure and it is related to distensibility of blood vessel. This in turn implies that the higher 
the compliance of a vessel, the more volume it can hold at a given pressure. Figure 4 shows the 
compliance profile of arteries and veins where arteries are shown to have a much lower 
compliance than that of the veins, which is represented by lower slope of the curve. In other 
words, at a certain pressure, arteries hold much less blood than the veins. This may provide 
explanation why arterial pressure is much higher compared to venous pressure.  
 
 The volume of blood in veins is called the unstressed volume (large volume under low 
pressure). While, the arteries are much less compliant and contain the stressed volume (low 
volume under high pressure). The total volume of blood in the cardiovascular system is the 
sum of the unstressed volume plus the stressed volume (plus whatever volume is contained in 
the heart) (Costanzo, 2018). 
1.1.3 Factors controlling blood pressure 
Blood flow through a blood vessel is determined by two factors: the pressure difference 
between the inlet and the outlet of the vessel, and the resistance of the vessel to blood flow.  
The relationship of flow, pressure, and resistance is analogous to the relationship of 
current (I), voltage (ΔV), and resistance (R) in electrical circuits, as expressed by Ohm's law 
Figure 4 Vascular compliance of arteries and veins 
(Costanzo, 2018) 
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(Ohm's law states that ΔV = I × R or I = ΔV/R). Blood flow is analogous to current flow, the 
pressure difference or driving force is analogous to the voltage difference, and hydrodynamic 






Where Q; flow (mL⋅min-1) which can be represented by cardiac output (CO), ΔP; 
pressure difference (mmHg) which can be represented by arterial and venous pressure, R; 
resistance (mmHg ⋅mL-1 per min) which can be represented by total peripheral resistance 







Where CO; cardiac output (ml⋅min-1), MAP; mean arterial pressure (mmHg), RAP; 
right atrial pressure (mmHg), TPR; total peripheral resistance (mmHg⋅min⋅ml-1) 
Since RAP is small and does not change markedly under most conditions, the usual 





Then, MAP can be described as  
𝑀𝐴𝑃 = 𝐶𝑂 ⋅ 𝑇𝑃𝑅 
Hence, Arterial BP is haemodynamically generated by the interplay between the cardiac 
output and the resistance to blood flow (Tarazi et al., 1989). 
1.1.3.1 Total peripheral resistance (TPR) 
The total peripheral resistance (TPR) represents the total resistance to the blood flow 
throughout the vasculature because of friction within the blood and between the blood and 
vessel walls. Most of the TPR is caused  by the arteriolar resistance, because arterioles are the 
primary resistance vessels (Sherwood, 2015).The diameter of blood vessels and blood viscosity 
are the main factors governing the TPR. The total resistance of a set of blood vessels depends 
on the arrangement of the blood vessels, as illustrated in Figure 5. Vasoconstriction increases 
resistance while vasodilation decrease the resistance (Hill et al., 2013). 
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Figure 5 Resistance of blood vessels (Costanzo, 2018) 
1.1.3.2 Cardiac output 
The cardiac output (CO) is the total volume ejected by each ventricle per unit time. 
Normally, the volume of blood flowing through the pulmonary circulation is the same as the 
volume flowing through the systemic circulation. Hence, the CO is almost the same from the 
two ventricles, with minor variations. 
The CO depends on the volume ejected on a single beat (stroke volume) and the number 
of beats per minute (heart rate) (see Figure 6). It can be represented as, 
𝐶𝑂 = 𝐻𝑅 ⋅ 𝑆𝑉 
, where HR: beats per minute (beats⋅min-1), SV: Volume ejected in one beat (mL) 
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1.1.3.2.1 Heart rate 
The heart rate (HR) represents the number of heartbeats per minute. The average resting 
HR is 70 beat per minute. The HR is regulated mainly by the sinoatrial node (SA), which is 
considered the pacemaker of the heart. The balance between parasympathetic inhibition of the 
SA node through the vagal nerve and stimulation by the cardiac sympathetic nerves is the 
primary determinant of the HR. Concurrent increased sympathetic and decreased 
parasympathetic activity cause the HR to increase, whereas the HR goes down with the 
simultaneous rise in parasympathetic activity and decline in sympathetic activity (Sherwood, 
2015). 
1.1.3.2.2 Stroke volume 
Stroke volume (SV) is the volume of blood ejected per beat by the left ventricle into 
the aorta, or from the right ventricle into the pulmonary artery. It can be estimated as the 
difference between the ventricular end-diastolic volume (EDV) and the end-systolic volume 
(ESV) which is determined by echocardiography when assessing ventricular function. Factors 
influencing the SV and their effects are summarised in Figure 7. 
1.1.3.2.2.1 Preload 
Preload is the degree of myocardial distension prior to shortening. It is best represented 
at the chamber level by the EDV of the left ventricle. Because volume is difficult to measure 
accurately and precisely in practice, preload is often estimated by left ventricle end-diastolic 
pressure. According to Frank-Straling law of the heart, an increase in venous return to the heart 
Figure 6 Summary of determinants of cardiac output (Mohrman and Heller, 2014) 
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increases the filled volume of the ventricle, which stretches the muscle fibres thereby 
increasing their preload. This leads to an increase in the force of ventricular contraction and 
enables the heart to eject the additional blood that was returned to it. Therefore, an increase in 
EDV results in an increase in SV. Conversely, a decrease in venous return and EDV leads to a 
decrease in SV by this mechanism (Braunwald et al., 2011). 
  
Frank-Starling law 
It states that the volume of blood ejected by the ventricle depends on the volume present 
in the ventricle at the end of diastole. Increased preload increases sarcomere stretch inside 
cardiac myocytes, which generates more force during contraction, and thereby allows the heart 
to eject more blood. However, there is a limit to the extent that this relationship can be 
maintained. In failing ventricles, overstretch can limit or decrease CO. In these cases, reducing 
myocyte stretch to a more optimal length can improve overall cardiac function (Figure 8) (Raj, 
2017). 
The volume present at the end of diastole depends on the volume returned to the heart, 
or the venous return. Therefore SV and CO correlate directly with EDV, which correlates with 
venous return. The Frank-Starling relationship governs normal ventricular function and ensures 
that the volume the heart ejects in systole equals the volume it receives in venous return. 
However, If preload continues to increase, the point of overstretch is reached and eventually 
passed. Cardiac output plateaus and then begins to fall. The plateaued segment is called the 
preload independent portion.  
Figure 7 factors affecting stroke volume (Klabunde, 2012) 
Chapter 1: Introduction 
 




Afterload is the force against which the ventricles must act in order to eject blood, and 
is largely dependent on the arterial blood pressure and vascular tone. When afterload increases, 
the SV drops (Vincent, 2008, Braunwald et al., 2011). 
1.1.3.2.2.3 Contractility 
Contractility, or the inotropic state, is the inherent capacity of the myocardium to 
contract independently of changes in preload or afterload. Sympathetic stimulation increase the 
heart contractility, which is the strength of contraction at any given EDV (i.e. for the same 
EDV a higher SV can be obtained). This in turn, causes a left shift for the Frank-starling curve 
(Figure 9) (Braunwald et al., 2011). 
Figure 8 Frank-Starling representation of the relationship between end diastolic volume (EDV), and stroke volume 
(SV) (Sherwood, 2015) 
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1.1.4 Regulation of blood pressure 
BP regulation is managed by short-term and long-term feedback control systems. 
Baroreceptor reflex is a neurally mediated short-term feedback working at a time scale of 
seconds to minutes to restore the BP toward its set point by altering the sympathetic, and 
parasympathetic signals to the CVS. The second system is the renin-angiotensin-aldosterone 
system (RAAS) which is hormonally mediated. It regulates BP more slowly (i.e. hours to days), 
primarily by its effect on blood volume. 
1.1.4.1 Baroreceptor feedback regulation of blood pressure 
Arterial baroreceptor, also called high-pressure baroreceptors, are the major receptors 
involved in the moment-to-moment regulation of blood pressure. They are located in the walls 
of the carotid sinus, and in the aortic arch. The carotid baroreceptors are responsive to both 
increases and decreases in arterial BP, whereas the aortic arch baroreceptors are primarily 
responsive to only increases in arterial BP (Sherwood, 2015, Armstrong M).  
Other baroreceptors are termed low-pressure baroreceptors or volume receptors, 
because of being located within the low-pressure venous system. They are located in large 
systemic veins, pulmonary vessels, and the right atrium and ventricle (Stanfield, 2013). 
Because of the greater vascular compliance of the venous system, these type of baroreceptors 
Figure 9 The influence of sympathetic stimulation on Frank-starling relationship (Sherwood, 2015). 
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are quite sensitive to blood volume change rather than pressure changes. They respond to 
dropped BP by stimulating the secretion of antidiuretic hormone, renin, and aldosterone 
(Armstrong M).  
The baroreceptor reflex functions as the major short-term negative feedback reflex that 
regulates arterial BP. Baroreceptors provide a dynamic signal to the brain regarding changes 
in BP and elicit reflex responses to maintain BP within a narrow range. They work as sensitive 
mechanoreceptors that stretch with increased BP by increased firing of the baroreceptors. This 
signal is delivered to the medullary cardiovascular centre, leading to an increase in 
parasympathetic outflow to the heart and a decrease in sympathetic outflow to the heart, 
arterioles, and veins. This induces a compensatory decrease in CO and TPR. Similarly, a 
decline in arterial pressure cause a decreased stretch in the baroreceptors and decreased firing  
rate resulting in increased cardiac output and vasoconstriction which ultimately increase BP 
(Armstrong M, Widmaier et al., 2019). Figure 10 summarises the baroreceptor response to 
decreased MAP. 
 
Figure 10 Arterial baroreflex to decreased mean arteria pressure. MAP: mean arterial pressure, EDV: end diastolic 
volume, HR: heart rate, SV: stroke volume, TPR: total peripheral resistance (Stanfield, 2013). 
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Baroreceptors are sensitive not only to the absolute level of pressure, but they are even 
more sensitive to the rate, and magnitude of changes in the BP. A rapid change in arterial BP 
acts as the strongest stimulus for the baroreceptors (Costanzo, 2018). Carotid baroreceptors are 
highly sensitive to the pulsatile profile of BP, i.e. the pulse pressure. The greater the oscillation 
in pressure around certain MAP, the greater the average baroreceptor activity. The role of this 
reflex becomes very significant during orthostasis and moderate haemorrhage, when there is a 
fall in PP due to the fall in SV, while having a subtle drop in MAP (Levick, 2013). 
Baroreceptors can adapt to changes of MAP that can develop at different physiological 
(e.g. postural changes, physical exercise) and pathological conditions (e.g. hypertension). This 
cause a shifting of the baroreceptor function curve to a higher or lower BP by resetting the 
functional set point based on the new prevailing MAP (see Figure 11). This includes 
maintaining the sensitivity to acute changes in BP but at a different set point. The baroreceptor 
reflexes ac primarily to stabilise BP within a narrow range rather than maintaining a normal 
level of BP (Raven and Chapleau, 2014, Widmaier et al., 2019).   
 
1.1.4.2 Renin-Angiotensin aldosterone system 
The renin angiotensin aldosterone system (RAAS) regulates BP mainly by regulating 
blood volume. RAAS works at a slower rate relative to the baroreflex, with a time scale of 
hours to days because of being hormonally, rather than neurally, mediated. A drop in BP 
Figure 11 Baroreceptor function curve resetting in hypertension and 
hypotension (Sved, 2009). 
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stimulates the RAAS with a cascade of activating several mediators to restore the BP back 
around the system set point (Widmaier et al., 2019).  
When the BP falls, the decreased renal perfusion pressure is sensed by the 
mechanoreceptors in afferent arterioles of the kidney. This in turn, stimulates the secretion of 
renin from the juxtaglomerular cell. Renin catalyses the conversion of angiotensinogen to 
angiotensin I (Costanzo, 2018). Angiotensin-converting enzyme (ACE) catalyses the 
conversion of angiotensin I to angiotensin II. Angiotensin II has several biological activities 
that ends up with restoring BP: 
 It stimulates the synthesis and secretion of aldosterone, which increases Na+ 
reabsorption from the renal tubules, and consequently the extracellular fluid volume 
and blood volume.  
 It has its own direct action on the kidney, independent of its actions through 
aldosterone. Angiotensin II  stimulates Na+-H + exchange in the renal proximal tubule 
and increases the reabsorption of Na+ increase extracellular fluid volume. 
 It also stimulates secretion of antidiuretic hormone (ADH), which increases water 
reabsorption in collecting ducts.  
 It acts directly on the arterioles to cause vasoconstriction. The resulting increase in TPR 
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1.2 Haemodynamic models 
Several attempts to develop mechanistic or semi-mechanistic models describing the 
CVS have been published. Some focused on describing the physiology of the CVS like 
Guyton’s model, which consisted of hundreds of mathematical equations that provided 
deep insights into the long-term regulation of BP and the role of the kidney in this (Guyton 
et al., 1972). Guyton’s model is considered a pioneer example of systems modelling 
approach. Other models integrated the knowledge of cardiovascular physiology with the 
haemodynamic effects of some drugs targeting the CVS using preclinical and clinical data 
(Francheteau et al., 1993, Chae et al., 2018, Snelder et al., 2014, Snelder et al., 2013). 
A summary description of previously published haemodynamic models in the literature 
is shown in Table 1.
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Table 1 Summary of previously published haemodynamic models 
Reference Short description Described feedback control 
system 
Comments 
(Francheteau et al., 
1993, Cheung et al., 
2012) 
A. Original model (Fracheteau et al.) 
(Francheteau et al., 1993) 
- Developed based on clinical data for 
healthy individuals receiving 
dihydropyridine (nicardipine and 
nifedipine) infusion 
- 3-state model (TPR, HR, U ‘feedback’) 
with a closed loop feedback control 
 - Considered feedback: baroreceptor 
reflex.  
- Feedback is a state variable, driven by 















-It acts on HR, TPR only  
- Changes in SV are not 
accounted for ‘SV 
assumed to be constant 
all the time’ 
- Feedback is working on 
HR, TPR only ‘has no 
effect on SV’ 
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- Delay between the arterial pressure 
change and the arterial pressure control 
was considered by 𝜏,  𝜏1, 𝜏2 
B. Adapted model (Cheung et al.) 
(Cheung et al., 2012) 
- Added a new model state for MAP 
- The influences of some model 
parameters were minimal in the model 
sensitivity analysis which indicates a 
potential unidentifability of the model 
- Reparametrised the model to reduce the 
model parameters 
(Snelder et al., 2014, 
Snelder et al., 2013) 
The two versions of the model were developed in 
rats, not validated in humans 
Snelder et al., 2013 (Snelder et al., 2013) 
- Developed using data from preclinical 
experiments with a training set of six 
antihypertensive drugs acting at different 
targets 
Considered feedback: baroreceptor 
reflex.  
Snelder et al., 2013  
- Feedback is described by 2 distinct 
system’s parameters to be estimated 
(FB1, FB2), acting on total peripheral 
- The model needs to be 
scaled and validated in 
humans as per the 
authors’ conclusion. 
- The model is locally 
identifiable when HR, 
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- consisted of two turnover equations 
cardiac output and total peripheral 
resistance, which were linked by 
negative feedback through MAP 
Snelder et al.,  2014 (Snelder et al., 2014) 
- the turnover equation for cardiac output 
was replaced by two turnover equations 
for heart rate and stroke volume 
- consisted of three linked turnover 
equations involving TPR, HR and SV all 








= 𝐾𝑖𝑛𝑆𝑉 ⋅ (1 − 𝐹𝐵 ⋅ 𝑀𝐴𝑃) − 𝑘𝑜𝑢𝑡𝑆𝑉
⋅ 𝑆𝑉∗ 
resistance, cardiac output, with between 
subject allowed on both of them. 
Snelder et al.,  2014 
- Feedback is a system’s parameter 
(shared by the different variables) to be 
estimated with baseline MAP as covariate 
using a power function 
- It acts on HR, SV, TPR 






MAP, CO measured 
together 
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= 𝐾𝑖𝑛𝐻𝑅 ⋅ (1 − 𝐹𝐵 ⋅ 𝑀𝐴𝑃) − 𝑘𝑜𝑢𝑡𝑇𝑃𝑅
⋅ 𝑇𝑃𝑅 




- The link between HR and SV is 
considered by a log-linear relationship 
(Chae et al., 2018) - Based on clinical data from healthy individual 
upon administration of telmisartan  
- A four-state model (heart rate, total peripheral 
resistance, pulse pressure, feedback) with a negative 
feedback closed control loop  
- Considered feedback: baroreceptor 
reflex.  
 
Assumes that the set 
point is time varying and 
the  system reset the 
baroreceptor to a 
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= 𝑘𝑂𝑈𝑇 ∙ 𝑆𝑃𝐻𝑅 − 𝑘𝑜𝑢𝑡 ∙ 𝐻𝑅 
𝑑𝑃𝑃
𝑑𝑡
= 𝑘𝑂𝑈𝑇 ∙ 𝑃𝑃0 ∙ (1 + 𝐹𝐵) − 𝑘𝑜𝑢𝑡 ∙ 𝑆𝑉 
𝑑𝐶𝑇𝑃𝑅
𝑑𝑡
= 𝑘𝑂𝑈𝑇 ∙ 𝐶𝑇𝑃𝑅0 ∙ (1 − 𝐷𝐸𝐹𝐹𝐸𝐶𝑇) − 𝑘𝑜𝑢𝑡
∙ 𝐶𝑇𝑃𝑅 + 𝐵𝑅 
𝑑𝐹𝐵
𝑑𝑡
= 𝑘𝑜𝑢𝑡 ∙ (𝐷𝑒𝑙𝑡𝑎 − 𝐹𝐵) 
- Feedback is a state variable driven by 
the fractional change in MAP relative to 





- It acts on heart rate,  and pulse pressure 
only 
-Baroreflex is another reflex signal acting 
on TPR , driven by the change in SV, HR 
𝐵𝑅 = −𝑇𝑃𝑅 ∙
𝛿𝑆𝑉
𝑆𝑉





direction opposing the 
perturbation  
 
𝑆𝑃𝐻𝑅 = 𝐻𝑅0 ∙ (1 + 𝐹𝐵) 
𝑆𝑃𝑃𝑃 = 𝑃𝑃0 ∙ (1 + 𝐹𝐵) 
𝑆𝑃𝐶𝑇𝑃𝑅
= 𝐶𝑇𝑃𝑅0
∙ (1 − 𝐷𝐸𝐹𝐹𝐸𝐶𝑇) 
𝑆𝑃𝑀𝐴𝑃 = 𝑆𝑃𝐻𝑅 ∙ 𝑆𝑃𝑃𝑃
∙ 𝑆𝑃𝐶𝑇𝑃𝑅 




- Feedback acts on HR, 
and pulse pressure, while 
baroreflex acts on TPR. 
 - The two feedback are 
distinct from each other, 
while working in 
opposite directions 
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(Coleman and Hall, 
1992, Guyton, 1990, 
Hallow and 
Gebremichael, 2017, 
Hallow et al., 2014, 
Karaaslan et al., 
2005) 
- In 1972, Guyton’s model was published. Further 
model refinement and expansions are still being 
published using the same core structure. 
- Large circulatory model of hundreds of equations 
mainly focused on describing the long-term 
regulation of blood pressure and the role of the 
kidney in this. 
- Explore the linkage between blood pressure and 
sodium balance and demonstrate the importance of 
renal salt and water balance in setting the long‐term 
blood pressure level. 
 
- Considered feedback: baroreceptor 
reflex and RAAS, , and control of arterial 
pressure by changes in body fluid 
volumes and electrolytes 
 
Like other complex 
systems models, using 
the model for estimation 
purposes is a bit 
challenging, considering 
the complexity of the 
model structure. 
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1.3 Sodium nitroprusside  
Sodium nitroprusside (SNP) is a potent vasodilator that has been used in clinical 
practice for a long time. SNP was first discovered in 1849; however, it was not until 1955 that 
Page et al. described the pharmacological effects of SNP in lowering the BP in severely 
hypertensive patients (Playfair, 1851, Page et al., 1955). In 1962, Moraca et al. investigated for 
the first time the clinical use and efficacy of SNP to induce deliberate hypotension during 
surgery in humans (Moraca et al., 1962). Since then, SNP has been introduced in perioperative 
settings as an effective fast-acting agent to induce intraoperative hypotension. Other indications 
for SNP included acute applications in hypertensive crises, heart failure, vascular surgery, and 
paediatric surgery (Hottinger et al., 2014).  
1.3.1 Mechanism of action 
1.3.1.1 Total peripheral resistance 
SNP acts as a prodrug that releases nitric oxide, causing rapid vasodilation, and acutely 
lowering BP. SNP releases nitric oxide by interacting with the sulfhydryl groups on 
erythrocytes, albumin, and other proteins.  This in turn stimulates a cascade of mediators ending 
up with vasodilation by stimulating guanyl cyclase enzyme to produce cyclic guanosine 
monophosphate, which causes sequestering of calcium and inhibiting cellular contraction. The 
net effect of nitric oxide is lowering the BP by reducing the vascular tone and the systemic 
vascular resistance. Sodium nitroprusside is more active on veins than on arteries (Tinker and 
Michenfelder, 1976). 
1.3.1.2 Baroreceptor resetting 
The effect of SNP on the resetting of the aortic baroreceptors has been suggested in 
some studies either in animals or in humans. Fritsch et al, studied the baroreceptor resetting in 
healthy normotensive volunteers upon infusion of SNP, and reported a significant change 
(resetting) of operational point (set point) toward a lower level of mean arterial pressure 
(Fritsch et al., 1989). 
The effect of SNP on resetting of normotensive rats to hypotension, and the reversal of 
resetting of baroreceptors of hypertensive rats to normotension was studied by Salgado et al,. 
They reported that the mechanism by which SNP causes baroreceptor resetting appears to be 
linked to affecting baroreceptor transduction (Salgado and Krieger, 1988, Deabreu and 
Salgado, 1990). Similar results were presented in conscious rabbits infused with SNP, where 
the decrease in MAP during SNP infusion lowered the baroreflex threshold for bradycardia. 
As a conclusion, the authors highlighted that arterial baroreceptors are triggered by a floating 
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rather than a fixed set point which is determined by the prevailing blood pressure steady state 
(Dorward et al., 1982). 
1.3.1.3 Tolerance and plasma renin activity 
Development of tachyphylaxis (i.e. rapid progressive tolerance to the effect) and 
rebound hypertension after stopping the SNP infusion has been reported before in the literature 
(Amaranath and Kellermeyer, 1976, Cottrell et al., 1978, Khambatta et al., 1979, Cottrell et al., 
1980, Delaney and Miller, 1980). One study was conducted on sixteen patients who were 
scheduled for major orthopaedic procedures. One group of the patients received SNP infusion 
while the others were pretreated with propranolol before SNP administration. The results of 
this study showed a significant increase of plasma renin activity (PRA) after 30 minutes of 
starting SNP infusion in patients who received SNP only, denoting that nitroprusside-induced 
hypotension activates the renin-angiotensin system. The PRA remained significantly elevated 
above the preinfusion levels after 15 minutes of SNP discontinuation. On the other hand, these 
changes in PRA were prevented by pretreatment with propranolol. These results showed that 
SNP administration triggers two opposing action: firstly,  vasodilatation due to a direct action 
of the drug on vascular smooth muscle, and secondly, vasoconstriction which is produced by 
compensatory increases in PRA. Because of the very short half-life of SNP as compared to 
renin, this may be explaining the progressive development of tolerance and rebound 
hypertension that may develop upon its abrupt withdrawal of SNP by leaving the 
vasoconstrictor renin effects unopposed. Propranolol pretreatment attenuates activation of the 
renin-angiotensin system, hence decreases SNP doses required to maintain hypotension, and 
prevents rebound hypertension observed following withdrawal of nitroprusside (Heuser et al., 
1985).  
Another study in humans showed that SNP infused to induce MAP reduction caused a 
significant sustained elevation of PRA above control levels for 30 min after cessation of SNP 
infusion. This was explained by the relatively slow decline in PRA with a half-life of 
approximately 30 min (Cottrell et al., 1980). 
1.3.2 Pharmacokinetics 
The onset of action of SNP is 1–2 min. The volume of distribution is approximately the 
same as the extracellular space. It reacts with the sulfhydryl groups on red blood cells, releasing 
cyanide and nitric oxide. Because it is rapidly cleared from the bloodstream by an 
intraerythrocytic reaction with haemoglobin, its effects dissipate within 1–10 min following 
discontinuation of therapy. The drug half-life is approximately 2 minutes. 
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1.3.2.1 Metabolism 
SNP is a water-soluble sodium salt comprised of ferrous complexed with nitric oxide 
and five cyanide anions. In the body, SNP is rapidly metabolised by a non-enzymatic electron 
transfer from the ferrous of free intracellular oxyhaemoglobin to nitroprusside yielding 
methaemoglobin and an unstable nitroprusside radical. This unstable radical breaks down 
rapidly releasing nitric oxide and five cyanide. The cyanide ions can then go through one of 
three pathways:  
i) binding to methaemoglobin yielding cyanomethaemoglobin 
ii) undergoing a reaction with thiosulfate and cobalamin in the liver catalysed by 
rhodanase forming thiocyanate which is excreted by the kidney 
iii) cyanide not otherwise removed binds to tissue cytochrome oxidase, thus 
uncoupling mitochondrial oxidative phosphorylation and inhibiting cellular 
respiration, even in the presence of adequate oxygen stores. This is considered 
the main reason acute toxicity of SNP 
The bioconversion of cyanide to thiocyanate is a saturable process, with the availability 
of sulphur-containing substrates as the limiting factor for this reaction. With prolonged 
administration or high doses of SNP, cyanide accumulates in the blood. The principal toxicity 
of SNP may be caused by the inactivation of cytochrome oxidase (Hottinger et al., 2014, Tinker 
and Michenfelder, 1976). 
1.3.3 Toxicity 
1.3.3.1 Cyanide toxicity 
Occurs typically at doses ≥ 10 mcg/kg/min where the toxic effects are rapid and fatal. 
Manifestation of cyanide toxicity include lactic acidosis, shortness of breath, cardiac 
arrhythmias, tachycardia, hypertension, central nervous system (CNS) dysfunction. Cyanide 
blood concentrations are usually not available. Cyanide toxicity can be assessed by monitoring 
serum electrolytes, serum lactate, and arterial blood gases (The Food and Drug Administration 
(FDA), 2017b). 
1.3.3.2 Thiocyanate 
It is a normal physiological component of serum that is renally cleared. The half-life is 
doubled or tripled in renal failure. Thiocyanate is mildly neurotoxic at serum levels of 1 
mmol/L and life-threatening when levels are 3 or 4 times higher. The toxicity is typically 
associated with high dose and prolonged infusions (e.g. >3mcg/kg/min or 1mcg/kg/min in 
anuric patients for >3 days). Thiocyanate levels should be closely monitored in patients with 
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prolonged infusions, impaired renal function, and those receiving simultaneous thiosulfate 
infusions (The Food and Drug Administration (FDA), 2017b). 
1.3.3.3 Methaemoglobinemia 
At healthy steady state, most people have less than 1% of their haemoglobin in the form 
of methaemoglobin. Clinically significant methaemoglobinemia (>10%) is rarely seen and it 
develops at exposure to very high doses of SNP. Methaemoglobinemia from excessive doses 
of SNP can be treated with methylene blue, which reduces methaemoglobin to haemoglobin 
(The Food and Drug Administration (FDA), 2017a, The Food and Drug Administration (FDA), 
2017b). 
1.3.4 Dosage and administration 
SNP is supplied as injection for intravenous infusion. The recommended start infusion 
rate is 0.3 mcg/kg/min with a maximum dose of 10 mcg/kg/min. Dose titration to the desired 
effect is recommended by close monitoring of BP during infusion. In patients with eGFR <30 
mL/min/1.73 m2, the mean infusion rate is limited to less than 3 mcg/kg/min. In anuric patients, 
the mean infusion rate is limited to 1 mcg/kg/min (The Food and Drug Administration (FDA), 
2017a). 
1.3.5 Clinical use 
SNP is a direct acting vasodilator indicated for instant reduction of BP, inducing 
controlled hypotension to reduce bleeding during surgery, and treatment of acute heart failure 
to reduce left ventricular end-diastolic pressure, peripheral vascular resistance, and mean 
arterial blood pressure(The Food and Drug Administration (FDA), 2017a). 
 1.4 Pharmacometrics 
Pharmacometrics is defined as “the science of developing and applying mathematical 
and statistical methods to characterize, understand, and predict a drug’s pharmacokinetic (PK), 
pharmacodynamic (PD), and biomarker-outcomes behaviour” (Ette and Williams, 2007). 
Pharmacometric applications include dose individualisation for different patient 
subpopulations, guiding study designs and initial dose selection, and understanding disease 
progression and drug-disease interaction (Mould et al., 2012).  
The present thesis implements pharmacometric approaches to model haemodynamics 
in humans and characterise the pharmacological effects of different drugs acting on the system. 
This section provides a brief introduction of the methods used in this thesis. 
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1.4.1 Models 
Models are simplified version of reality. They help provide a better understanding of 
the modelled system. Models however are usually developed to fit the purpose of their intended 
use rather than to have the level of granularity of capturing the related system(s) completely. 
This was articulated by the British statistician George Box aphorism about models; 
“Essentially, all models are wrong, but some are useful” (Box and Draper, 1987). Quantitative 
modelling of drug effects and interactions with biological systems is an emerging tool in drug 
development (Mould et al., 2012). 
1.4.1.1 PK model 
PK is concerned with characterising different processes of drug in the biological system 
including absorption, distribution, metabolism, and excretion (ADME). PK models aim to 
describe and predict the time course of drug concentrations, which play an integral role in the 
development and clinical use of drugs (Mould et al., 2013). The complexity of PK models 
varies from simple empirical compartmental models to more complex mechanistic models and 
physiologically based PK (PBPK) models.  
1.4.1.2 PKPD model 
PKPD models are concerned with describing the time course of drug effect by allowing 
the drug PK “drug concentration” to drive the PD “drug effect”. The link between the PK and 
PD is captured by either direct effect models “immediate response” or indirect effect models 
“delay models”, based on the presence of lag time between having a measurable drug 
concentration and effect development (Upton and D, 2014). 
1.4.1.3 QSP model 
Despite the wide application of PKPD modelling in providing predictive guidance for 
dose response, having a limited biological relevance restricts its utility in extrapolating data 
between different physiological systems, for instance healthy and pathological (Mager et al.). 
Quantitative Systems Pharmacology (QSP) is an emerging modelling approach, which includes 
a great emphasis on the biology and physiology of the target system. QSP approaches, in 
comparison to other modelling approaches, are concerned with describing and quantifying the 
complex interaction between drugs and the human body. Moreover, they provide deeper 
insights into complex systems dynamics such as biological feedbacks, generate information on 
the mechanism of action and drug effects, and allow the assessment of disease 
progression(Kloft et al., 2016, Peterson and Riggs, 2015). 
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1.4.2 Modelling approaches. 
 Three approaches have been adopted in pharmacometric modelling. These include: the 
data driven approach, “top-down”; mechanism based approach, “bottom-up”; and middle out 
approach (Tylutki et al., 2016). 
1.4.2.1 Top-down approach 
This approach involves the development of empirical models driven by the data and 
achieving the parsimony of model parameters with less attention to capture the underlying 
physiology or pharmacology. Empirical models usually have limited application beyond the 
range of the input data. 
1.4.2.2 Bottom-up approach 
In bottom-up approach, mechanistic models are developed fully based on known 
mechanisms and they are generally more complex in their structure as compared to empirical 
models. They focus more on modelling the system information, providing deeper insight into 
complex physiological systems. Unlike the top-down approach, bottom-up approach allows 
model extrapolation to a wider range of scenarios far beyond the data limit, based on the level 
of complexity of the developed model.  
1.4.2.3 Middle-out approach 
This approach combines bottom-up and top-down approaches by allowing the observed 
data to inform unknown or uncertain parameters of the mechanism-based model. In the context 
of the current thesis, we consider QSP model and semi-mechanistic models as an application 
of middle out approach. This approach was applied in Chapter 2 where a minimal 
haemodynamic model is developed and Chapter 3 where we combined the developed model 
with haemodynamic data to characterise the effects of SNP. 
1.4.3 Population analysis 
Population analyses model individual data while accounting for the sources of 
variability between and within individuals in model parameters. Population models use mixed 
effect model estimation, which include both fixed and random effect parameters.  
Fixed-effect parameters are model elements that do not vary across individuals. They 
reflect the typical values, or central tendencies, of the structural model parameters for the 
population. 
Random-effect parameters are model elements that characterise the different sources of 
variability in the population. They include two levels: Level 1 (L1), which describes the 
magnitude of unexplained variability in parameters between population individuals (Between 
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subject variability ‘BSV’); and Level 2 (L2), which quantifies the error in model predictions 
for multiple dependent variables (Residual unexplained variability ‘RUV’).  
Overarching aim of the current thesis 
The current thesis applies pharmacometric methods to provide a mechanistic modelling 
of haemodynamics in humans and to show model application to haemodynamic data from 
adolescents who received SNP.  The motive behind this work was the lack of mechanistic 
haemodynamic models in humans that adequately capture the interrelationships between 
different haemodynamic variables while maintaining the model parsimony to allow model use 
for estimation purposes. This in turn served as the basis to evaluate the model performance in 
characterising the haemodynamic effects of SNP in adolescents by considering the different 
postulations about the mechanism of action of SNP. 
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2.1 Introduction 
Haemodynamics describes the pressure and flow of blood through the circulatory 
system.  It is governed by cardiac output (CO) and the resistance of the blood vessels (Secomb, 
2016, Klabunde, 2012). Tracking changes and the status of haemodynamics are essential parts 
of monitoring disease progress and the efficacy of drugs that act on the cardiovascular system 
(CVS) (Collins et al., 2015).  
In clinical practice, blood pressure (BP), assessed by systolic (SBP), diastolic (DBP), 
and mean arterial pressure (MAP), and heart rate (HR) are the most commonly monitored 
haemodynamic variables. The fundamental relationships between these variables are well 
established (Levick, 2009). The haemodynamics of the CVS can be described by a closed-loop 
control system, where the MAP is closely regulated through adaptive changes in heart rate 
(HR), stroke volume (SV), total peripheral resistance (TPR), and blood volume (Raven and 
Chapleau, 2014). However, it remains common for many PKPD models to describe the 
haemodynamic variables separately without accounting for the interrelationship between these 
variables. While this is appropriate for descriptive models, e.g. (Caruso et al., 2014, Collins et 
al., 2015, Hocht et al., 2014), these models may lack the ability to accommodate extrapolation 
to situations that extend beyond the range of the data, e.g. the investigation of new drug targets.  
Attempts to mechanistically model the cardiovascular regulation of BP date back to 
1972 when Guyton and his colleagues published a large systems based circulatory model. The 
model focused on describing the long-term BP control with emphasis on the renal role in BP 
regulation (Guyton et al., 1972). This work remains a pioneer of quantitative systems analysis 
(Montani et al., 2009). Since then, model refinement and extended versions of the model are 
still being published, as a part of quantitative systems modelling, to describe the 
pathophysiology of hypertension and kidney disease (Hallow and Gebremichael, 2017, Hallow 
et al., 2014, Coleman and Hall, 1992, Guyton, 1990, Karaaslan et al., 2005). However, like 
other complex systems models, the focus of these models is to understand the physiology, 
disease progression, and drug mechanisms, while facing challenges for using such complex 
models for estimation purposes (Ribba et al., 2017). 
There are a limited number of simpler published models with structures that account 
for the mechanistic interrelationships between the haemodynamic variables (i.e. MAP, HR, SV 
and TPR) and the feedback control loop (see (Francheteau et al., 1993, Chae et al., 2018, 
Snelder et al., 2014) for examples). A common feature of these models is the quantification of 
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the interrelationship between variables and the short-term feedback signal as represented by 
the baroreceptor reflex. However, different implicit model assumptions underpin these models. 
In Francheteau’s model, SV was assumed to be constant, which could limit model application 
in other scenarios where significant changes in SV develop (e.g. haemorrhage, diuretics, 
plasma expanders) (Francheteau et al., 1993). The work of Snelder provided a simple effective 
control system but has not been extended beyond rats and dogs (Snelder et al., 2014, 
Venkatasubramanian R  et al., 2016). Although Chae’s model was used to describe the 
haemodynamics upon receiving a drug acting on TPR, the feedback control considered only 
cases where TPR is the site of system’s perturbation, so the model may not have the flexibility 
to describe drugs acting on other drug targets (i.e. HR, SV) (Chae et al., 2018). Hence, to our 
knowledge there are no published models that accommodate the necessary features of the 
haemodynamic BP control for ready use in pharmacometric modelling.   
The overall goal of the current work is to develop a minimal haemodynamic model that 
can be used by any investigator to quantify and understand the mechanistic effects of 
pharmacological agents on the short-term haemodynamics of the CVS in humans.  It is intended 
that this model would be used for estimation purposes in top-down modelling applications (e.g. 
using NONMEM) for any situation in which BP, HR, and CO are measured either together or 
in isolation. This model with supporting documentation is available as an open source at 
GitHub (https://github.com/SalmaBahnasawy/SysModel.git). 
The specific aims of the study were to: (i) build a minimal model to describe short-term 
haemodynamic changes, (ii) evaluate the model to characterise the haemodynamic profiles 
under different-target perturbations, (iii) apply the model to clinical data extracted from the 
literature, and (iv) check the structural identifiability of the model under different conditions 
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2.2 Methods 
2.2.1 Model development  
 A minimal model was developed to describe the short-term haemodynamics in humans. 
The model structure was adapted from Chae’s model (Chae et al., 2018). This section shows 
the key features of the proposed model structure.  
2.1.1 Interrelationship between MAP and HR, SV, and TPR 
Over a period greater than one cardiac cycle the time averaged expression for cardiac 
output can be written, 𝐶𝑂 = 𝐻𝑅 ⋅ 𝑆𝑉, which yields the simple solution for 𝑀𝐴𝑃,  
𝑀𝐴𝑃 = 𝐻𝑅 ⋅ 𝑆𝑉 ⋅ 𝑇𝑃𝑅 (1) 
The proposed minimal model does not accommodate the influence or change in arterial 
compliance over time and therefore does not define pulse pressure required to determine SBP 
and DBP.  These components are generally not needed when describing the short-term 
haemodynamic influence of drugs over minutes to days. 
2.1.2 The turnover rate of BP recovery  
We use a turnover rate constant,  𝑘𝑜𝑢𝑡, to reflect the recovery rate of system to the 
reference BP. It is assumed to be shared by all model state variables (i.e.𝑇𝑃𝑅, 𝐻𝑅, and 𝑆𝑉) as 
it is affected by a common autonomic control system. Furthermore, the current model assumes 
that the turnover rate of all the haemodynamic changes happens over a time scale of minutes 
rather than hours, so in all the subsequent simulations 𝑘𝑜𝑢𝑡 was fixed to a suitably high value, 
reflecting a short reflex half-life of the system. 
2.1.3 MAP set point  
 A set point for MAP is incorporated to derive the baroreceptor reflex. In this context, a 
set point is a reference point to which the body tries to return the BP as a part of homeostasis. 
This would be seen as the steady state MAP value (𝑀𝐴𝑃𝑆𝑆 under no perturbation) being equal 
to the set point for MAP (𝑀𝐴𝑃𝑆𝑃), 
𝑀𝐴𝑃𝑠𝑠 = 𝑀𝐴𝑃𝑆𝑃  . (2) 
If the system is started at a steady state and unperturbed initial condition then,  
𝑀𝐴𝑃𝑆𝑃 = 𝑀𝐴𝑃𝑠𝑠   . (3) 
The baroreflex feedback is driven by the relative difference of the current MAP from 
the reference MAP set point which is defined by the fractional change in MAP (𝑓𝑐𝑀𝐴𝑃) ; 
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 . (4) 
2.1.4 Inverse relationship between HR, SV  
The current model structure considers an inverse relationship between 𝐻𝑅 and 𝑆𝑉. This 
in turn, can account for the decline in 𝑆𝑉  that could develop at high 𝐻𝑅  because of the 
shortening of the cardiac diastolic interval and left ventricle filling time. Snelder et al described 
this relationship using a log-linear relationship between 𝐻𝑅 and 𝑆𝑉 (Snelder et al., 2014),  
𝑆𝑉 =  𝑆𝑉𝑁 ⋅ [1 − 𝛽 ⋅ 𝑙𝑛 (
𝐻𝑅
𝐻𝑅|𝑀𝐴𝑃=𝑀𝐴𝑃𝑆𝑃   
)] (5) 
In this equation, 𝛽 is a constant that represents the magnitude of the direct effect of 𝐻𝑅 
and 𝑆𝑉 , 𝐻𝑅|𝑀𝐴𝑃=𝑀𝐴𝑃𝑆𝑃    is the 𝐻𝑅  evaluated at MAP equal to  𝑀𝐴𝑃𝑆𝑃  (which we term 
𝐻𝑅|𝑀𝐴𝑃𝑠𝑠 hereafter (as per equation (3) under ideal conditions), while 𝑆𝑉𝑁 is the value of  𝑆𝑉 
normalised to  𝐻𝑅|𝑀𝐴𝑃𝑠𝑠  . 
2.1.5 Mean arterial pressure is calculated 
The SBP and DBP pressures are determined as a function of pulse pressure and MAP, 
where pulse pressure is a function of arterial compliance.  In this work, we do not incorporate 
the SBP and DBP, hence have not incorporated components of pulse pressure into the 
calculation. In the clinical setting, it is usual to measure SBP and DBP rather than MAP, which 
requires an invasive technique (Klabunde, 2012). In these circumstances, MAP can be 




  . (6) 
2.1.6 Feedback control defined as baroreflex 
The present model structure assumes a closed-loop control structure for the system 
where baroreceptor reflex is a negative feedback control (i.e. system damping) acting on the 
three main components that drive MAP (i.e. 𝑇𝑃𝑅, 𝐻𝑅, 𝑎𝑛𝑑 𝑆𝑉 ). The site of system’s 
perturbation or the primary drug target does not influence this.  
2.1.7 General model structure 
A turnover model, composed of four states, was used to describe the model structure. A 
typical representation for a generic variable (𝜈) is  
𝑑(𝑣)
𝑑𝑡
= 𝑅𝑖𝑛 − 𝑘𝑜𝑢𝑡 ⋅ 𝑣  , (7) 
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where 𝑅𝑖𝑛 is the zero-order production rate and k_out the first-order dissipation rate constant.  
In the context of baroreflex these concepts are empirical. At steady state 
𝑅𝑖𝑛 = 𝑘𝑜𝑢𝑡 ⋅ 𝑣𝑠𝑠   , (8) 
 where 𝑣𝑠𝑠 is the variable at steady state. 
An empirical 𝐸𝑚𝑎𝑥  model was used to link the drug concentration to drug effect 




  ,  (9) 
where 𝐸𝑚𝑎𝑥   is the maximum fractional drug effect that could be achieved (termed as 𝐼𝑚𝑎𝑥 for 
inhibitory drug effect), 𝐶𝑝  is the drug plasma concentration, and 𝐶50  the concentration 
producing half of the maximum effect. Note any relevant drug effect model could be used. 




= 𝑅𝑖𝑛 ⋅ (1 ± 𝐷𝑒𝑓𝑓𝑒𝑐𝑡) − 𝑘𝑜𝑢𝑡 ⋅ 𝑣  (10) 
The drug effect function could be added to affect the production or dissipation of the 
variable, based on its mechanism of action. Note, since dissipation is under overall system 
control it is perhaps unlikely to be the main site of drug action. While the dissipation of system 
states is somewhat complicated in a conceptual sense to consider, it is reasonable biologically. 
The purpose of dissipation is to allow the system to return to its set-point after perturbation 
(e.g. by a drug).  Since the return to basal conditions is not instantaneous then the delay is 
considered as a parameter in the model.  In the present model all changes in the system are 
controlled by kout  (the “dissipation” rate constant) which then specifies that (within the 
confines of normal physiology) haemodynamic processes have a delay in their response to 
normal physiological perturbations and to the influence of pharmacological interventions.   
2.2.2 Evaluation of the model 
The performance of the model was evaluated under two different simulation settings to 
explore its performance. All model simulations were performed in MATLAB R2017a 
(MATLAB, 2017). 
2.2.1 System perturbation for different targets 
A hypothetical scenario was simulated in which a patient with hypertension received a 
hypotensive drug by infusion that was stopped after one hour and the haemodynamic profiles 
 Chapter 2 : A minimal haemodynamic model in humans 
36 | P a g e  
 
were tracked until return to the set point. The drug effect was simulated under three scenarios 
representing an inhibitory effect on 𝑇𝑃𝑅, 𝐻𝑅,  or 𝑆𝑉 . The simulated drug followed a one-
compartment PK model with a linear elimination.  
The aim of the simulation was to explore the behaviour of the model performance in 
describing haemodynamic changes to perturbation of the system. In order to minimise the 
influence of drug-related changes in exposure (i.e. PK) on the system a rapidly eliminated drug 
was simulated. The drug parameters used for simulations are (R= 1000 mcg⋅hr -1, k=10 hr -1, 
V=1 L, Imax =0.5, C50= 50 mcg⋅L-1).  
The purpose of this simulation was to evaluate the model flexibility to capture changes 
of different haemodynamic variables that can arise by perturbing the system at different targets. 
Furthermore, to explore the system’s ability to stabilise the BP back around the set point after 
stopping the source of perturbation. 
2.2.2 System perturbation when baroreceptor reflex is switched off 
The model was used to simulate the effect of perturbing 𝑆𝑉 with and without 
baroreflex.  To switch off the baroreflex signal, the rate of change of baroreflex state was 
assumed to be zero (i.e. 
𝑑𝐵𝑅
𝑑𝑡
= 0). For this simulation, only the 𝑆𝑉 was changed. No drug was 
added. The SV was increased over a certain interval period (0.5-1 hour) by a step function, 
𝑆𝑉0 = {
𝑆𝑉|𝑀𝐴𝑃𝑠𝑠                                         , 𝑎𝑡 𝑡 < 0.5 , 𝑡 ≥ 1
𝑆𝑉|𝑀𝐴𝑃𝑠𝑠 + 𝑝𝑒𝑟𝑡𝑢𝑟𝑏𝑎𝑡𝑖𝑜𝑛         , 𝑎𝑡 0.5 ≤   𝑡 < 1
  , (11) 
where 𝑆𝑉|𝑀𝐴𝑃𝑠𝑠  is 𝑆𝑉 evaluated at steady state MAP (equation 6). 
The purpose of this simulation was to compare the haemodynamic profiles (especially 
of the non-directly perturbed variables) with and without the influence of feedback reflex.  
2.2.4 Application of the model 
Haemodynamic data were extracted from the literature using WebPlotDigitizer, 4.2 
(Rohatgi). Initial conditions and the set point for MAP were calibrated to the reported initial 
values of the observed data assuming that the patient’s baseline is the same as patient’s set 
point (i.e. ‘the system starts at steady state, 𝐵𝑅0 = 0’). Simulations were performed under the 
reported mean plasma concentration-time profile, with an 𝐸𝑚𝑎𝑥 model linking the drug PK to 
the PD. To account for the variability in the reported concentrations, we simulated at the upper 
and lower bounds of the concentration (mean ± standard deviation).  Two drug targets, HR and 
TPR were considered. In all cases, the simulations were overlaid on the observed data. 
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2.4.1 A drug inhibiting HR 
The data (i.e. SBP, DBP, HR, and drug plasma concentrations) arose from a study of 
metoprolol, a 𝛽1  selective adrenergic-antagonist, in fourteen female patients with mild 
essential hypertension. Heart rate was the primary drug target. Six patients received 80 mg and 
eight patients received 50 mg oral doses three times daily. Simulations were performed for the 
haemodynamic profiles obtained over six hours after a single oral administration under the two 
dosing levels using the reported mean plasma concentration (Bengtsson et al., 1975). 
2.4.2 A drug inhibiting TPR 
In this scenario, the haemodynamic effects of nifedipine, one of the dihydropyridine 
calcium channel blockers with a primary target of TPR, were simulated. Data on SBP, DBP, 
HR, and drug plasma concentrations were extracted from a previously published study on 
sublingual administration of nifedipine 10 mg to 11 patients and 20 mg to 6 patients with 
arterial hypertension  (Pedersen and Mikkelsen, 1978). Patients with secondary hypertension 
were excluded. The average plasma concentrations over two hours after single dose 
administration were reported for the two dosing levels (seven patients on 10mg and six patients 
on 20 mg). 
2.2.5 Structural identifiability analysis  
Structural identifiability is related to the structure of the underlying mathematical 
model. It is concerned with whether the parameters of a model can be uniquely identified from 
a given experiment with perfect input-output data (Shivva et al., 2013). A structural 
identifiability analysis was performed to evaluate the use of the model with various 
combinations of data that might arise in clinical practice. The system was assumed to start at 
an unperturbed steady state. The MATLAB toolbox, STRIKE-GOLDD MATLAB (Villaverde 
et al., 2016), was used for this evaluation. An identifiability analysis was considered under four 
combinations of observed variable availability, 
i. MAP, HR, and CO measured 
ii. MAP and HR measured 
iii. MAP measured only 
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2.3 Results 
2.3.1 Model structure 
The model quantifies the interrelationships between the haemodynamic variables (HR, SV 
and TPR) driving the blood pressure (i.e. MAP). The current model is composed of four states 
capturing the changes in the haemodynamics of the CVS by a closed-loop control system, 
where the MAP is closely regulated through adaptive changes in HR, SV, and TPR. The  short-
term feedback signal is represented by the baroreceptor reflex, which is driven by the fractional 
change from the systems set point of MAP. 
The model structure is illustrated in Figure 12 with model states shown as boxes. The model 
is represented by four ordinary differential equations (ODEs): 
𝑑(𝐻𝑅)
𝑑𝑡
= 𝑘𝑜𝑢𝑡 ∙ 𝐻𝑅0 ⋅ (1 − 𝐵𝑅) − 𝑘𝑜𝑢𝑡 ∙ 𝐻𝑅 
𝑑(𝑆𝑉𝑁)
𝑑𝑡
= 𝑘𝑜𝑢𝑡 ∙ 𝑆𝑉𝑁0 ⋅ (1 − 𝐵𝑅) − 𝑘𝑜𝑢𝑡 ∙ 𝑆𝑉𝑁 
𝑑(𝑇𝑃𝑅)
𝑑𝑡
= 𝑘𝑜𝑢𝑡 ∙ 𝑇𝑃𝑅0 ⋅ (1 − 𝐵𝑅) − 𝑘𝑜𝑢𝑡 ∙ 𝑇𝑃𝑅 
𝑑(𝐵𝑅)
𝑑𝑡
= 𝑘𝑜𝑢𝑡 ⋅ (𝑓𝑐𝑀𝐴𝑃 − 𝐵𝑅) 
SV =  SVN ⋅ [1 − β ⋅ ln (
HR






𝑀𝐴𝑃 = 𝐶𝑂 ⋅ 𝑇𝑃𝑅 =  𝐻𝑅 ⋅ 𝑆𝑉 ⋅ 𝑇𝑃𝑅 
The initial values were given by 
𝐴0 = [𝐻𝑅0, 𝑆𝑉𝑁0, 𝑇𝑃𝑅0, 𝐵𝑅0] 
 When 𝑣0 = 𝑣|𝑀𝐴𝑃𝑠𝑠 (𝑖. 𝑒. 𝐻𝑅0, 𝑆𝑉𝑁0, 𝑇𝑃𝑅0), then the initial value for baroreflex can be fixed 
to zero (i.e. 𝐵𝑅0 = 0).  
A description of model system parameters (𝑘𝑜𝑢𝑡, 𝛽, 𝑀𝐴𝑃𝑆𝑃) , with the values used for the 
model simulations, and the initial conditions (𝐻𝑅0, 𝑆𝑉𝑁0, 𝑇𝑃𝑅0, 𝐵𝑅0) is represented in Table 
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2. The initial conditions used for each simulation were calibrated to the data. Model calibration 






Figure 12 Model schematic.  𝑆𝑉: stroke volume, 𝑆𝑉𝑁 : stroke volume normalised to a standard heart rate, 𝐻𝑅: 
heart rate, 𝑇𝑃𝑅: total peripheral resistance, 𝐶𝑂: cardiac output, MAP: mean arterial pressure, 𝑀𝐴𝑃𝑆𝑃 : MAP 
set point, 𝐵𝑅: baroreflex, 𝑓𝑐𝑀𝐴𝑃: fractional change in MAP.  Circles indicate calculated variables, while boxes 
indicate model states. Solid lines indicate causal calculations, dashed lines indicates a negative feedback 
control, positive or negative signs represent the mathematical property. 
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Table 2 description of model system’s parameters and initial conditions 
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2.3.2 Evaluation of the model 
2.3.2.1 System perturbation for different targets 
In the three scenarios, the profiles of primary drug targets are represented in pink and 
the secondary changes that developed on other haemodynamic variables are shown in purple 
(Figure 13).  The shared feature in these scenarios is that they all show a recovery of MAP to 
the system set point after the source of perturbation has been discontinued. In addition, the 
corresponding changes in the non-directly targeted haemodynamic variables illustrate how this 
closed-loop control system is working at different perturbation scenarios. For instance, when a 
drug inhibits TPR with an overall decrease of MAP, then HR, SV and therefore CO increase 




Figure 13 Simulation profiles upon one-hour infusion of a hypotensive drug in a hypertensive patient. Each column 
represents a simulation scenario for the drug primary target. The pink solid line represents the drug effect on the primary 
target; the purple line represents the secondary corresponding profiles. 
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2.3.2.2 System perturbation when baroreceptor reflex is switched off  
Figure 14 depicts the influences of perturbing the system by a step function increase of 
𝑆𝑉  while switching on/off the feedback control. A more pronounced increase in MAP, 𝑆𝑉, 𝐶𝑂 
developed when switching off the feedback (dashed line) as compared to keeping the feedback 
on (solid line). Moreover, while the non-targeted haemodynamic variables (i.e. 𝐻𝑅, 𝑇𝑃𝑅) were 
inhibited as a feedback reflex (solid lines), they remained constant when the feedback was 
switched off (dashed line). In all the cases, the system returns back to the system set point as 
long as the source of perturbation is cleared (as whendrug is cleared from the body, the system 
return to its initial state regardless of  having feedback control or not). The difference will be 
about the level of change in BP rather than getting back to the system set point. 
 
Figure 14 The haemodynamic profiles with a step function perturbing the stroke volume between 0.5-1 
hour. The pink line represents the primary target perturbation; the purple line represents the 
secondary corresponding profiles. Solid line represents the model prediction under the baroreflex 
feedback control; dashed line represents the model prediction when the baroreflex is switched off. 
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2.3.3 Application of the model 
Model application to clinical data showed an overall good description of the reported 
data without fitting.  The overlay profiles of simulations and literature data for the different 
simulation scenarios (i.e. drug inhibiting 𝐻𝑅 or 𝑇𝑃𝑅) are shown in Figure 15 and Figure 16, 
respectively. The model simulations are shown using solid lines and the data are filled squares. 
The coloured bands represent the prediction intervals by simulating the drug effect considering 
the variability of reported drug concentration. For these simulations, the initial conditions and 
set point were calibrated to the reported data. Other system parameter were fixed based on the 
physiological plausibility, and reported literature estimates (𝑘𝑜𝑢𝑡 = 35 ℎ
−1, 𝛽 = 0.22).  Note 
that these simulations represent the mechanistic structure of the model, as the parameters were 
not estimated. 
The model use for estimation purpose in both of drug examples is shown in the 
Appendix 1 (Section A.1) with the model estimates, NONMEM code and overlaid plots of the 
simulated and estimated profiles. 
 
Figure 15 Overlaid haemodynamic profiles of metoprolol after a single oral dose in 14 patients with mild essential 
hypertension. Each data point represented by a square with bars represents the mean of the observed data ± SD (n=8 for 
50mg dose, n=6 for 80mg dose). Solid lines represent the simulated profiles based on the extracted mean plasma 
concentration. The shaded area represents the simulated haemodynamic profiles under the reported drug plasma 
concentration ± SD 
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2.3.4 Structural identifiability analysis 
The structural identifiability analysis revealed all model parameters and initial 
conditions were identifiable when 𝐻𝑅, MAP, and CO were measured together (assuming the 
system to start at a non-perturbed state, i.e. 𝐵𝑅0 = 0). A summary of identifiability analysis 
results are represented in Table 3. It should be noted that the parameter 𝑘𝑜𝑢𝑡 may be difficult 
to estimate if its value represents a fast dissipation of the system relative to the haemodynamic 
perturbation.  In which case its value can be fixed to a suitably large value, (we use 35 ℎ−1, 
reflecting a half-life of approximately 1.2 minutes). 
Table 3 Structural identifiability results 
Observed variable Identifiable parameters/ 
initial conditions 
Parameter to be fixed 
𝐻𝑅, 𝑀𝐴𝑃, and 𝐶𝑂 𝑘𝑜𝑢𝑡, 𝑀𝐴𝑃𝑆𝑃, 𝛽, 𝐻𝑅0, 𝑆𝑉𝑁0 NA 
𝐻𝑅, and 𝑀𝐴𝑃 𝑘𝑜𝑢𝑡, 𝑀𝐴𝑃𝑆𝑃, 𝛽, 𝐻𝑅0  𝑆𝑉𝑁0 
MAP only  𝑘𝑜𝑢𝑡, 𝑀𝐴𝑃𝑆𝑃 , 𝛽 𝐻𝑅0, 𝑆𝑉𝑁0 
𝐻𝑅 only 𝑘𝑜𝑢𝑡, 𝛽, 𝐻𝑅0 𝑀𝐴𝑃𝑆𝑃, 𝑆𝑉𝑁0 
 
 
Figure 16 Overlaid haemodynamic profiles of nifedipine after a single sublingual dose in hypertensive patients. Each data 
point represented by a triangle with bars represents the mean of the observed data ± SD (n=11 for 10mg dose, n=6  for 
20mg dose). Solid lines represent the simulated profiles based on the extracted mean plasma concentration. The shaded 
area represents the simulated haemodynamic profiles under the reported drug plasma concentration ± SD. 
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2.4 Discussion 
In the current work, we present a minimal model structure that can describe the short-
term haemodynamic changes of the cardiovascular system. The model quantifies the 
interrelationship between haemodynamic variables of clinical interest (i.e. MAP, HR, SV, 
TPR) including describing the closed-loop control system. We define short term as control that 
occurs over minutes to hours rather than longer-term control (days to weeks) involving the 
renal system.  The model was applied to MAP and HR data extracted from the literature for 
nifedipine and metoprolol.  In both cases, the minimal model was applied with the original set 
of parameters (see Table 2).  In this setting no parameter estimation was performed.  The model 
with original parameter values provided an accepted description of the data.  This implies the 
model has an appropriate level of mechanistic plausibility to capture both the scale of the data 
and also the necessary feedback components.  Further simulations by perturbing SV provided 
an illustration of the flexibility of the minimal model particularly in relation to baroreceptor 
reflex. 
We note the turnover rate constant of the recovery of BP was estimated in Chae’s model 
in the time scale of hours reflecting a BP recovery half-life of 10.34 hour. This, in turn, means 
that the system reaches the steady state in about 40 hours. However, this could not 
accommodate rapid feedback reflex that develops upon abrupt drop in BP as in loss of blood 
volume, which is known to take place in a few minutes (Schadt and Ludbrook, 1991). One 
possible explanation for their estimated slow rate is that their model considered telmisartan–
receptor interaction linked with the cardiovascular response as a single unit. It is therefore not 
possible to disentangle the pharmacodynamic activity of the drug from the system (Chae et al., 
2018). In this case, the apparent slow turnover of the haemodynamic system would be 
controlled by the rate-limiting step, which might be the slow turnover rate of the mediator 
related to the pharmacology of the drug at the receptor site. The minimal model would provide 
an opportunity to consider the haemodynamic system as a separate system at which the drug 
exerts its action.  Under this assumption, it would therefore be possible to examine the profile 
of the drug-receptor interaction. 
The turnover model was used as a parsimonious empirical delay model (with only one 
parameter ‘𝑘𝑜𝑢𝑡  ’) to describe the short delay which is under the control of the autonomic 
nervous system to maintain homeostasis. This provides the necessary characteristics in 
modulating the balance between the sympathetic and parasympathetic impulses to control the 
haemodynamic variables and allows return to the resting state at a defined recovery rate 
(governed by 𝑘𝑜𝑢𝑡  ). Other delay models could have been used. 
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The baroreceptor reflex functions as the major short-term damping control of the system 
that opposes the direction of system perturbation. Baroreceptors can adapt to different 
physiological stressors like postural change or exercise, as well as sustained pathological 
conditions as in hypertension. For instance, for hypertensive patients the baroreceptors 
continue to oppose minute to-minute changes in BP, but this occurs at a different resting value 
of the system, which implies that they accommodate a higher BP recovery set point (Sved, 
2009, Widmaier et al., 2019). It is also possible that as the set-point shifts from the normal 
value (e.g. normotensive value) that the baroreceptor feedback efficiency also changes.  
However, we were not able to explore this in this work. Including MAP set point as a distinct 
component in the current model structure, gives the model the flexibility to describe the 
mechanism of action of some drugs that were reported to cause baroreceptor resetting (Zhang 
and Wang, 2001, Salgado and Krieger, 1988).  
An identifiability analysis was implemented for the current model structure. All model 
parameters and initial conditions can be estimated when MAP, HR, and CO were measured. 
(Table 3). In other scenarios, some of the model parameters/initial conditions need to be fixed 
to keep the model identifiable. For instance, if only HR, and MAP were measured, then the 
initial condition of SV state needs to be fixed. This table is designed to provide guidance on 
how to use the model under different scenarios of the measured variables. 
For model application, even though in the examples explored here, random effects were 
not considered as, individual level data were not available; the model is amenable to the 
addition of random effects to describe between-patient differences. 
The baroreceptor activity response to changes in MAP is usually represented by a 
sigmoid curve (Sved, 2009). The carotid baroreceptors respond to pressures ranging from 60-
180 mmHg. Maximal baroreceptors sensitivity occurs around the set point of MAP. Hence, 
small changes in MAP around this set point highly affect receptor firing so that autonomic 
control can be altered in such a way that the MAP remains very near to the set point (Klabunde, 
2012). This could be a limitation when applying the model at extreme changes of BP, where a 
linear relationship may not yield appropriate response. 
It is important to note that the model depends on MAP measurements to derive the 
haemodynamic profiles. For most clinical settings, MAP is not directly measured due to the 
invasiveness of the technique. Hence, usually MAP is calculated from SBP and DBP based on 
the knowledge that two thirds of normal cardiac cycle is spent in diastole and one third in 
systole. However, at high 𝐻𝑅, MAP is more closely approximated by the arithmetic mean of 
SBP and DBP as the aortic pulse wave becomes shorter. Different formulas have been proposed 
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to account for 𝐻𝑅 changes when calculating MAP (Moran et al., 1995, Razminia et al., 2004). 
This could be a limitation of the model in situations of high rates of HR as in high intensity 
exercise where this relationship may not be constant. An extension of the model to 
accommodate pulse pressure and arterial compliance would accommodate this, which is the 
subject of future work. In addition, we anticipate the model may have a limited capacity to 
accommodate specific receptor level pharmacological profiles of tolerance or rebound effects. 
However, this could still be captured by expanding the current model structure to include other 
states describing the mediators that could be involved in developing such profiles based on the 
suggested underlying mechanisms in the literature. 
2.5 Conclusions 
We have described a minimal model of the haemodynamic system.  Evaluation of the 
model suggests that its mechanistic plausibility is able to accommodate observed data profiles. 
It is intended that the minimal model could be used as the basis of standard pharmacokinetic-
pharmacodynamic analysis of haemodynamic data in humans.   
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3.1 Background 
Controlled hypotension is a technique that has been used to limit intraoperative blood 
loss, reduce the need for blood transfusions, and improve visualisation of the surgical field. It 
is achieved by reducing the systolic blood pressure to 80 – 90 mmHg, reducing mean arterial 
pressure (MAP) to 50 – 65 mmHg, or causing a 30% reduction of baseline MAP (Moraca et 
al., 1962).  
Several drugs have been used to induce controlled hypotension in paediatric surgery. 
These include calcium channel blockers, beta-adrenergic antagonists, ganglionic blockers, 
inhalation anaesthetics, and direct-acting vasodilators such as nitroglycerin and sodium 
nitroprusside (Degoute, 2007, Tobias, 2002). 
Sodium nitroprusside (SNP) is a direct-acting vasodilator that has been used in 
paediatrics to induce deliberate hypotension in perioperative settings. SNP has a potent 
vasodilation effect on venous and arterial smooth muscle that effectively decreases systemic 
vascular resistance producing its hypotensive effect (Hottinger et al., 2014). Although SNP is 
commonly used in paediatric patients during surgery, information about the safety and 
effectiveness of SNP in this population has been scant and its use had been extrapolated from 
clinical trials in adults.  
SNP is a nitric oxide donor, which inhibits the vascular resistance with a net 
hypotensive effect. Moreover, some studies postulated the effect of SNP on resetting the 
arterial baroreceptors by shifting the set point of MAP to a hypotensive level. 
In 2002, the United States Food and Drug Administration (FDA) issued a request for 
paediatric studies on SNP to Abbott Laboratories, as the holder of the new drug application of 
SNP. The approved labelling of nitroprusside use in paediatric patients for controlled 
hypotension lacked adequate information on dosing, pharmacokinetics, tolerability, and safety. 
The National Institutes of Health (NIH) in the United States issued a request in 2004 for 
proposals to conduct paediatric studies and awarded funds to Duke and Stanford Universities 
to conduct these studies. A report of the results of two paediatric studies of SNP was submitted 
for review to the NIH and the FDA in 2012 (Food and Drug Administration, 2014). 
The first SNP study was a randomised double-blind, parallel-group, dose-ranging, 
effect-controlled, multicentre study and included 203 paediatric patients requiring short term 
SNP infusion for inducing controlled hypotension during surgery (Drover et al., 2015). The 
second study enrolled 63 intensive care paediatric patients who started with an open-label 
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prolonged SNP infusion followed by a double-blinded randomisation to either placebo or SNP 
(Hammer et al., 2015).  
Results of the two studies provided safety and efficacy data and established a 
preliminary dosing guideline for paediatric SNP administration in perioperative settings. The 
key findings of these two studies showed the blood pressure (BP) lowering effectiveness of 
SNP, indicated that patients on higher doses of SNP were more likely to achieve the target 
MAP and at a faster rate, and suggested 0.3μg/kg/min as a reasonable starting dose of SNP in 
paediatric patients requiring controlled hypotension (Food and Drug Administration, 2014). 
However, the remaining challenges with SNP dosing were the difficulty to maintain the 
patient’s BP within the target window since more than half of the time the BP was not within 
the target range, and the large unexplained variability in patient sensitivity to the drug  (Drover 
et al., 2015). 
Spielberg et al., have implemented linear regression analysis for the results of one of 
these two studies to explore the patient and clinical related factors that may affect BP control 
during deliberate hypotension in the study population. They studied several factors including 
the dose, dosing frequency, type of surgery, site of care, patient age, and baseline MAP. 
However, they reported a poor predictive capacity of the studied factors upon applying either 
univariate or multivariate regression model analysis for BP control. Hence, the analysis of 
covariates that may quantitatively predict the SNP hypotensive effect was not sufficient to 
reduce dose-response variability or improve BP prediction in individual patients. Most of the 
variability in BP control for an individual patient was due to unidentified factors and it was not 
feasible to predict accurately whether BP can be kept around the target MAP during deliberate 
hypotension (Spielberg et al., 2014). 
Another analysis has been performed where a KPD model was developed to help guide 
the dosing of SNP in paediatrics. The model revealed that there were two subpopulations of 
patients having different sensitivities to SNP, but no correlations between the subpopulations 
and covariates were found. The model reported two 𝐶50 (460 and 138 μg/L) with population 
distributions of 70:30%, respectively. None of the investigated factors was sufficient to explain 
different drug sensitivities (Barrett et al., 2015). Hence, in their recommendations, they 
highlighted the need to work on developing a more mechanistic pharmacokinetic-
pharmacodynamic characterisation to expand knowledge of SNP effects. This will in turn allow 
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better understanding of the variability in SNP response and provide guidance for SNP dosing 
for better BP control (Spielberg et al., 2014).   
The developmental changes in the haemodynamic variables (e.g. SV, HR, and TPR) 
are linked to body size changes and physiologic maturation in children and adolescents. This 
has been described using different allometric power functions per each age stratum (Gillum et 
al., 1982, de Simone et al., 1997, Ma et al., 2012, Dewey et al., 2008). BP levels in turn are 
correlated with body size measurements (e.g. height, weight, and body mass index) in children 
and adolescents. Defining the cut-offs for normal range of BP within the different age strata 
helps diagnose abnormal haemodynamics (e.g. hypertension) that could develop in children 
and adolescents. The American Academy of Pediatrics (AAP) 2017 Guidelines for 
hypertension in children and adolescents define sex, age, and height percentile-adjusted SBP 
and DBP values in children <13 years old. However, for adolescents ≥ 13 years old, the adult 
blood pressure thresholds of defining hypertension have been adopted because of the closeness 
of the percentiles of adolescents to the adults’ normal BP levels (Flynn and Falkner, 2017, 
Flynn et al., 2017). 
The aim of the present work is to develop an extended PKPD (ePKPD) i.e. “semi-
mechanistic” model that can describe the haemodynamic effects of SNP in adolescents and 
explain the different sensitives to the drug. 
3.2 Methods 
3.2.1 Data description 
The data arose from a multi-centre, randomised, double-blinded, parallel group dose-
ranging study to examine the safety and efficacy of SNP in paediatric patients requiring 
controlled reduction of blood pressure during surgery (Drover et al., 2015).  
3.2.1.1 Study design 
The study design involved four study phases (see Figure 17) 
I. Pre-study drug administration (PRE) 
• A period of up to 24 hours preceding the start of surgery.  
• Patient demographics and vital signs were recorded and patients 
were randomly allocated to treatment groups. 
• Baseline blood pressure was defined as the average of at least two 
pressure measurements in the preceding one minute prior to the 
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initiation of sodium nitroprusside after a 5-minute period of stable 
anaesthesia or sedation.   
II. Blinded treatment phase (BTP) (not all patients completed this phase) 
• After stabilisation of anaesthesia and measurement of vital signs, 
participants began the BTP. 
• Patients were administered a blinded dose of SNP (0.3, 1, 2, and 3 
µg/kg/min) for up to 30 min. 
• The blinded dose was initiated at one-third of the full infusion rate 
for 5 min, then increased to two-thirds of the full rate for 5 additional 
minutes, then the dose was increased to the full rate if the target 
MAP was not attained. 
• Followed by a washout period (BT2) until patient baseline 
haemodynamics are attained. Patient haemodynamics were recorded 
during this phase as well. 
• BTP was discontinued if MAP fell below 50 mm Hg (40 mm Hg in 
neonates) or heart rate (HR) exceeded the age-adjusted maximum, 
or an adverse event occurred that was judged to be possibly related 
to the study drug. 
III. Open-label treatment phase (OTP) (not all the patients entered this phase) 
• This phase lasted at least 90 min, during which time SNP was 
initiated at a dose deemed appropriate by the investigator and was 
gradually adjusted to reach a target MAP defined by the investigator 
for each individual patient, in keeping with the clinical presentation 
and the needs of the patient. 
IV. Follow-up phase (FUP) 
• Started immediately after infusion of the study drug and ended 
after 30 days. 
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3.2.1.2 Study population 
The study included 203 paediatric patients who required intra-operative deliberate 
hypotension for at least 2 hours. Different types of surgical procedures were identified 
including spinal fusion, craniofacial reconstruction, coarctation of the aorta repair, and cerebral 
angiography. The study population age ranged from 3 days to 17 years old (see Figure 18).  
The current analysis included data from adolescents only (age ≥ 13 years old), with a 
total number of 86 individuals. Summary statistics of the baseline demographics of the current 
analysis population is shown in Table 4. 
 
Figure 18 Histogram of age distribution of the study population 
Figure 17 schematic of the study phases. PRE: pre-study drug administration period where patients were initiated and stabilised 
on anaesthesia; BTP: blinded treatment phase; BT2: blinded treatment phase II; OTP: open-label phase; FUP: follow-up phase 
(Drover et al., 2015) 
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Table 4 Summary statistics of baseline demographics for adolescents ≥ 13 years old  
 
3.2.1.3 Data collection 
The principal method of obtaining blood pressure measurements was from an intra-
arterial catheter inserted in an upper or lower extremity artery.  In participants with coarctation 
of the thoracic aorta, a right upper extremity artery was used prior to surgical repair. In other 
patients, the choice of insertion sites, in order of priority, was (1) radial, (2) femoral, and (3) 
axillary. The MAP recorded from each of these sites is generally considered comparable. 
Manual blood pressures from a non-invasive blood pressure cuff was only used prior to 
insertion of and during a malfunction of the arterial catheter. All blood pressure, heart rate, and 
oxygen saturation data were acquired electronically from a monitor when possible.    
Intensive sampling of patient haemodynamic variables (MAP, HR, SBP, and DBP) was 
performed during BTP, with average recording frequency of 2 minutes. The plasma 
concentrations of SNP were not feasible to obtain because of the rapid drug metabolism, 
chemical instability, and short half-life. 
3.2.1.4 Current analysis 
The current analysis included: 
 Study population: adolescents only (age ≥13 years). This age cut-off was chosen 
based on the AAP 2017 Guidelines for hypertension in children and adolescents 
 
 
Treatment group dose (μg/kg/min )  
Total 
(N=86) 
0.3           
(N=20, 23.3%) 
1             
(N=21, 24.4%) 
2             
(N=26, 30.2%) 
3           
(N=19, 22%) 
Age (years) 
Mean(SD) 14.74(1.04) 14.86(1.09) 15.03(1.12) 15.10(1.15) 14.93(1.09) 
Min-Max 13.11-16.75 13.03- 16.51 13.14-16.69 13.59-17.01 13.03-17  
Weight (kilograms) 
Mean(SD) 51.85 (13.24) 58.78(22.42) 55.31(14.39) 54.56(14.7)
  
55.19(16.4) 
Min-Max 29.6-73.9 28.3-112.2 28.5-93.4 34.8-84.2 28.3-112.2 
Sex 
Male 3 8 11 4 26 (30.2%) 
Female 17 13 15 15 60(69.76%) 
Chapter 3: A semi-mechanistic model of nitroprusside in adolescents 
55 | P a g e  
 
which adopted the adult blood pressures thresholds for all adolescents ≥ 13 
years old (Flynn et al., 2017). 
 Study phase: data from BTP phase only because the study details for this 
phase were available whereas not the case for OTP. 
 Dependant variables: MAP and HR as these are the response variables 
included in the minimal haemodynamic model (chapter 2). 
3.2.1.5 Data exploration 
 The haemodymaic profiles for the population (adolescents) during the blinded phase 
of SNP intravenous infusion is represented in Figure 19. 
 
Figure 19 Spaghetti plots of individual haemodynamic profiles of adolescents during the blinded treatment phase. MAP: 
mean arterial pressure; HR: heart rate. 
3.2.2 Model structure  
3.2.2.1 Model extension 
The extension of the minimal haemodynamic model developed in chapter 2 was 
conducted in order to describe SNP haemodynamic effect is described below. The minimal 
model was defined based on known mechanisms and included MAP, HR, and SV and four 
states described by differential equations. Model extension was informed by the postulated 
mechanisms for drug mechanism of action and physiologic haemodynamic response as 
reported in the literature. 
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3.2.2.1.1 Potential drug targets 
3.2.2.1.1.1 Total peripheral resistance 
The primary target of SNP is inhibiting total peripheral resistance (TPR) by releasing 
nitric oxide. This ultimately causes vasodilation of blood vessels, and consequently reduction 
of blood pressure. The description of SNP pharmacokinetics and pharmacodynamics is detailed 
in section 1.3. 







= 𝑘𝑜𝑢𝑡 ∙ 𝑇𝑃𝑅0 ⋅ (1 − 𝐵𝑅) ⋅ (1 − 𝐷𝑒𝑓𝑓𝑒𝑐𝑡) − 𝑘𝑜𝑢𝑡 ∙ 𝑇𝑃𝑅 
where 𝐼𝑚𝑎𝑥   is the maximum fractional inhibitory drug effect that could be achieved, 𝐶𝑝 is the 
drug plasma concentration, and 𝐶50 the concentration producing half of the maximum effect.  
3.2.2.1.1.2 Baroreceptor resetting 
Some studies have reported the influence of SNP on the resetting of the aortic 
baroreceptors by affecting the baroreceptor transduction, as elaborated in section 1.3.1. The 
current structure accounted for the postulated mechanism of baroreceptor resetting by adding 
the drug effect on the baroreceptor state 
𝑑(𝐵𝑅)
𝑑𝑡
= 𝑘𝑜𝑢𝑡 ⋅ 𝑓𝑐𝑀𝐴𝑃 ⋅ (1 − 𝐷𝑒𝑓𝑓𝑒𝑐𝑡) − 𝐵𝑅 
, where 𝑓𝑐𝑀𝐴𝑃 is the fractional change in MAP 
3.2.2. 1.1.3 Tolerance and plasma renin activity (PRA) 
Tachyphylaxis development upon infusion of SNP has been linked to increased plasma 
renin activity. The detailed mechanism and supporting evidence from literature is mentioned 
in section 1.3.1. To account for the proposed mechanism of tachyphylaxis and rebound 
hypertension with SNP infusion, a new state was added to the minimal model structure shown 
in chapter 2. This state describes the changes in the plasma renin activity (PRA), with a turnover 
rate constant 𝑘𝑃𝑅𝐴  
𝑑(𝑃𝑅𝐴)
𝑑𝑡
= 𝑘𝑃𝑅𝐴 ⋅ (𝑓𝑐𝑀𝐴𝑃 − 𝑃𝑅𝐴) 
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In the current model, PRA is considered to affect the turnover of TPR, causing by opposing 
the direction of change in TPR; 
𝑑(𝑇𝑃𝑅)
𝑑𝑡
= 𝑘𝑜𝑢𝑡 ∙ 𝑇𝑃𝑅0 ⋅ (1 − 𝐹𝑃𝑅𝐴 ⋅ 𝑃𝑅𝐴) − 𝑘𝑜𝑢𝑡 ∙ 𝑇𝑃𝑅 
3.2.2.1.3 Drug pharmacokinetics 
There was no pharmacokinetic data available in the dataset, because of the rapid 
metabolism of SNP and difficulty to measure the plasma concentration of either SNP or nitric 
oxide, which are known to have very short half-lives as elaborated in section 1.3.3. A simple 
one-compartment PK model for SNP and nitric oxide representing nitroprusside metabolism 
was added to the model, assuming first order elimination of SNP and nitric oxide (Figure 20). 
 
 
Figure 20  Pharmacokinetic model of sodium nitroprusside infusion. SNP: sodium nitroprusside, CN: cyanide, NO: nitric oxide, 
TPR: total peripheral resistance, BR: baroreceptor reflex 
 
The elimination rate constants of SNP and nitric oxide were fixed in this setting based 
on the reported half-life of both compounds in the literature (Hakim et al., 1996, Simmonds et 
al., 2014, Ivankovich et al., 1978), while the volume of distribution was assumed to be 1 L. 
𝑑(𝑆𝑁𝑃)
𝑑𝑡
= 𝑅𝑖𝑛 − 𝑘10 ∙ (𝑆𝑁𝑃) 
𝑑(𝑁𝑂)
𝑑𝑡
= 𝑘10 ∙ (𝑆𝑁𝑃) − 𝑘20  ∙ (𝑁𝑂) 
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where, 𝑅𝑖𝑛 is the infusion rate of SNP, 𝑘10 is the first order elimination rate constant of SNP, 
𝑘20 is the first order elimination rate constant of nitric oxide 
 
3.2.3 Model simulation and calibration 
The simulations were conducted in MATLAB R2017a (MATLAB, 2017). Only 
deterministic simulation was considered without accounting for between-subject variability. 
The parameter values were calibrated based on the physiological plausibility and reported 
literature estimates. 
In this simulation, a single dose of a 30-minute infusion of SNP was added to the 
system. The different haemodynamic profiles were simulated under two conditions, 
considering the suggested increased renin activity and assuming no significant changes develop 
in the renin activity. To switch off the PRA signal, the rate of PRA state change was assumed 




The aim of this simulation was to obtain the signature profile of different 
haemodynamic variables that can arise with and without considering the increased PRA, and 
to calibrate the initial parameter estimates that provided a reasonable starting position for 
estimation. For this simulation, the drug parameters used are (R= 4000 mcg⋅ℎ−1, 𝑘10=20.8ℎ
−1, 
𝑘20=1250ℎ
−1, V=1 L, 𝐼𝑚𝑎𝑥 =1, 𝐶50= 3 mcg⋅L
-1). The MATLAB simulation code is provided 
in Appendix 2 (section A.2.1). 
3.2.4 Model estimation 
Model estimation was performed using a nonlinear mixed-effects model framework in 
NONMEM version 7.3.0 (ICON Development Solutions, Ellicott City, MD, United States). 
First-order conditional estimation method with interaction (FOCE-I) was used for model 
fitting. Model runs were executed using Perl-Speaks-NONMEM 4.5.0 (PsN), Pirana 2.9.0 and 
Xpose 0.4.8. An exponential model was used to describe the between-subject variability (BSV) 
and an additive residual error model (RUV) was used. For these estimations, model parameters 
were relaxed one at a time in a stepwise manner, where the run that causes the highest drop in 
the objective function value is selected. For nested models, the likelihood ratio test (LRT) was 
used whereby a reduction in OFV of ≥ 3.84 represents a statistically significant difference for 
one degree of freedom. The BSV parameters ( 𝜔2)  were tested to be added to eligible 
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parameters one at a time in the same manner. Model selection was informed by the minimum 
objective function value, goodness of fit plots, and parameter value biological plausibility. 
Model evaluation was based on the visual inspection of goodness of fit of individual plots. 
Two different scenarios for SNP mechanism of action were considered in model 
estimation based on the reported mechanisms in literature as elaborated in section 1.3.1 ; (a) 
affecting TPR only, (b) affecting both TPR and baroreceptors (i.e. combined mechanism). 
3.3 Results 
3.3.1 Model structure 
The final model structure used to describe the haemodynamic effects of SNP consisted 
of seven states (two states describing the PK of SNP and five states describing the changes in 
haemodynamic variables of concern and the feedback signals). The model schematic is shown 
in Figure 21. 
𝑑(𝑆𝑁𝑃)
𝑑𝑡
 =  𝑅𝑖𝑛 −  𝑘10 ⋅ [𝑆𝑁𝑃] 
𝑑(𝑁𝑂)
𝑑𝑡
 =  𝑘10 ⋅ [𝑆𝑁𝑃]  −  𝑘20 ⋅ [𝑁𝑂]                                        
𝑑(𝐻𝑅)
𝑑𝑡
= 𝑘𝑜𝑢𝑡 ∙ 𝐻𝑅0 ⋅ (1 − 𝐵𝑅) − 𝑘𝑜𝑢𝑡 ∙ 𝐻𝑅 
𝑑(𝑆𝑉𝑁)
𝑑𝑡
= 𝑘𝑜𝑢𝑡 ∙ 𝑆𝑉𝑁0 ⋅ (1 − 𝐵𝑅) − 𝑘𝑜𝑢𝑡 ∙ 𝑆𝑉𝑁 
𝑑(𝑇𝑃𝑅)
𝑑𝑡
= 𝑘𝑜𝑢𝑡 ∙ 𝑇𝑃𝑅0 ⋅ (1 − 𝐵𝑅) ⋅ (1 − 𝐷𝑒𝑓𝑓𝑒𝑐𝑡) ⋅ (1 − 𝐹𝑃𝑅𝐴 ⋅ 𝑃𝑅𝐴) − 𝑘𝑜𝑢𝑡 ∙ 𝑇𝑃𝑅 
𝑑(𝐵𝑅)
𝑑𝑡
= 𝑘𝑜𝑢𝑡 ⋅ 𝑓𝑐𝑀𝐴𝑃 ⋅ (1 − 𝐷𝑒𝑓𝑓𝑒𝑐𝑡) − 𝐵𝑅 
𝑑(𝑃𝑅𝐴)
𝑑𝑡





𝑆𝑉 =  𝑆𝑉𝑁 ⋅ [1 − 𝛽 ⋅ 𝑙𝑛 (
𝐻𝑅






𝑀𝐴𝑃 = 𝐶𝑂 ⋅ 𝑇𝑃𝑅 =  𝐻𝑅 ⋅ 𝑆𝑉 ⋅ 𝑇𝑃𝑅 
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The initial values were given by 
𝐴0 = [𝑆𝑁𝑃0, 𝑁𝑂0, 𝐻𝑅0, 𝑆𝑉𝑁0, 𝑇𝑃𝑅0, 𝐵𝑅0, 𝑃𝑅𝐴0] 
When 𝑣0 = 𝑣|𝑀𝐴𝑃𝑠𝑠 (𝑖. 𝑒. 𝐻𝑅0, 𝑆𝑉𝑁0, 𝑇𝑃𝑅0), then the initial value for baroreflex and plasma 
renin activity can be fixed to zero (i.e.𝐵𝑅0 = 0, 𝑃𝑅𝐴0 = 0).   
  
 
3.3.2 Model simulation and calibration 
Figure 22 depicts the haemodynamic effects of SNP infusion on the different variables 
with and without considering the possibility of increasing the PRA. It is noted that a resistance 
Figure 21 Haemodynamic model for sodium nitroprusside considering the drug affecting both total 
peripheral resistance and baroreceptors.SV: stroke volume, 𝑆𝑉𝑁 : stroke volume normalised to a standard 
heart rate, HR: heart rate, CO: cardiac output, TPR: total peripheral resistance, MAP: mean arterial 
pressure, 𝑀𝐴𝑃𝑆𝑃: MAP set point, fcMAP: fractional change in MAP, BR: baroreceptor, PRA: plasma renin 
activity. Circles indicate calculated variables, while boxes indicate model states. Solid lines indicate causal 
calculations, dashed lines indicates a negative feedback control, positive or negative signs represent the 
mathematical property. 
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to the effect of SNP on MAP starts to develop over the infusion window (without a 
corresponding change in SNP level) when the PRA state is considered (solid line), as compared 
to switching off this state (dashed line). In addition, when the PRA state is considered (solid 
line), upon stopping the infusion, the TPR and MAP get back to a higher than baseline level 
and gradually return to the baseline level. This corresponds to the increased level of PRA that 
does not instantly get back to normal with stopping the infusion (solid line). The same 
behaviour is observed with the non-directly targeted haemodynamic variables (𝑆𝑉, 𝐻𝑅), but in 
the opposite direction, where they drop to lower than baseline levels and return gradually to 
the baseline levels. 
Figure 22 Signature profile of different haemodynamic variables upon a 30-minute infusion of sodium nitroprusside. Solid 
line represents the model prediction under the PRA feedback control; dashed line represents the model prediction when the 
PRA is switched off. SNP: sodium nitroprusside, MAP: mean arterial pressure, HR: heart rate, TPR: total peripheral 
resistance, SV: stroke volume, PRA: plasma renin activity 
3.3.3 Model estimation 
The final model was developed based on the data from 86 patient with 2617 
observations of the dependent variables MAP and HR. In the final model, it was considered 
that SNP has a dual effect on both peripheral resistance and resetting of the baroreceptors (i.e. 
a combined mechanism), since it provided a better model fit compared to affecting peripheral 
resistance only. A single 𝐸𝑚𝑎𝑥 function was used to account for this dual effect, since it was 
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revealed by different model runs that considering two 𝐸𝑚𝑎𝑥 functions for the two targets has 
no benefits on either model fitting or stability. 
Because the two dependent variables were measured at the same time points (every two 
minutes), part of the measurement error (e.g. sample record time) is expected to be correlated 
across the dependent variables. To account for this correlation arising between the RUV items, 
correlation in the level-two (L2) data item was considered by adding L2 data item in the dataset 
and modelling a full sigma matrix for the RUV. In NONMEM, the L2 data item is used to 
group together observations that have the same realisation of the residual unidentified 
variability. 
Standard residual variability models assume the same residual variability magnitude for all 
individuals; however, this assumption can be violated with rich data because of the presence 
of outliers. Allowing between-subject variability on the magnitude of residual variability 
provides weighting across individuals. Because of the rich sampling schedule in the current 
study, outliers were accounted for by adding BSV on the RUV.  
The differences in patients sensitivities to SNP (e.g. some patients developed tachyphylaxis 
or were resistant to SNP) were considered by assuming a system parameter for the fraction of 
plasma renin activity (𝐹𝑃𝑅𝐴). There were two patient subpopulations for drug sensitivity with 
differences in PRA elicited by SNP infusion (i.e. two 𝐹𝑃𝑅𝐴, with population contribution of 
67:33%). 
In the current analysis, the drug related pharmacokinetic parameters (since there is no PK 
data) and system parameters (because of model stability issues) were fixed during the 
estimation runs based on the reported values in the literature, and the physiological plausibility. 
Only drug related PD parameters, initial conditions and BSV parameters were allowed to be 
estimated. The final parameter estimates are shown in Table 5. The NONMEM estimation code 
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−𝟏) The first order elimination rate 
constant of nitroprusside 
20.8*  
𝒌𝟐𝟎 (𝒉
−𝟏) The first order elimination rate 
constant of nitric oxide 
1250 *  
𝑽(𝑳) Volume of distribution of nitric oxide 1 *  
Initial conditions 
𝑺𝑽𝟎(𝒎𝒍 ⋅ 𝒃𝒆𝒂𝒕
−𝟏) Stroke volume initial condition 70 *  
𝑯𝑹𝟎(𝒃𝒆𝒂𝒕 ⋅ 𝒎𝒊𝒏
−𝟏) Heart rate initial condition 81.4 22 [4%] 
𝑴𝑨𝑷𝟎 (𝒎𝒎𝑯𝒈) Mean arterial initial condition 79.1 13.9[5%] 
System- related parameters 
𝒌𝒐𝒖𝒕(𝒉
−𝟏) The first order dissipation rate 
constant of the systems four state 
variables 
25 *  
𝒌𝑷𝑹𝑨(𝒉
−𝟏) The first order dissipation rate 
constant of plasma renin activity 
1.5 *  
𝜷 (uniteless) A scalar for the log-linear 
relationship of heart rate and stroke 
volume 
0.212 *  
Drug PD parameters 
𝑰𝒎𝒂𝒙 (uniteless) The maximum inhibitory fractional 
drug effect that could be achieved 
1 *  
𝑪𝟓𝟎 (𝝁𝒈 ⋅ 𝑳
−𝟏) The nitric oxide concentration 
producing half of the maximum 
inhibitory effect. 
2.99 131[12%] 
Probability of low PRA  0.692  
𝑭𝑷𝑹𝑨 – low (uniteless) The fraction of plasma renin activity 
for the subpopulation with low 
plasma renin activity 
0.01 *  
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𝑭𝑷𝑹𝑨 –  high 
(uniteless) 
The fraction of plasma renin activity 
for the subpopulation with high 




𝟐  [ɛ𝒔𝒉%] 
 




𝟐  [ɛ𝒔𝒉%] 
 
Additive RUV on heart rate 47.4[1%] 57.9[4%] 
𝒄𝒐𝒗𝝈 (𝒄𝒐𝒓𝒓%) Covariance between the L2 data item 5.35(10.3%)  
*Fixed parameter  
CV; Coefficient of variation  
 
3.3.4 Model evaluation  
Individual plots for MAP and HR were plotted considering the infusion rate (black solid 
line) as a secondary y-axis to give an indication of how the haemodynamic response was 
influenced by the change in infusion rate. In addition, the target predetermined MAP for each 
patient was added to the plots as a guide to elaborate how the decision to up titrate or terminate 
the infusion rate was taken.   
For most patients, there was a general alignment between observations and the model 
individual predictions (IPRED). However, predictions at the population level (PRED) were 
generally not well aligned with observations. Some patients (e.g. ID 31, ID 56, and ID 177) 
could not be described by even IPRED, since they showed unexplained haemodynamic 
response (e.g. increased MAP upon SNP infusion) which is not supported by the mechanistic 
underlying of the model as shown in Figure 24. 
Some patients showed a development of resistance (i.e. tachyphylaxis) to the effects of 
SNP, exhibiting an initial drop in MAP followed by a gradual increase in MAP with no change 
of SNP infusion rate. Figure 23 shows the individual plots for patients developing 
tachyphylaxis, and how the IPRED provides a good description for this pattern of response. 
A sample of individual plots for some patients for MAP and HR are shown in Figure 
25 and Figure 26. The individual plots for all the patients is provided in Appendix 2 (Section 
A.2.3) 
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Figure 23 individual plots of some patients showing tachyphylaxis upon infusion of nitroprusside. The black solid line represents 
the infusion rate of nitroprusside. 
Figure 24 individual plots of patients who showed increased mean arterial pressure upon infusion of nitroprusside. The black 
solid line represents the infusion rate of nitroprusside. 
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Figure 25 A sample of individual plots of mean arterial pressure versus time. The black solid line represents the infusion rate of 
nitroprusside. 
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Figure 26 A sample of individual plots of heart rate versus time. The black solid line represents the infusion rate of nitroprusside. 
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3.4 Discussion 
The current work presents an evaluation of the minimal haemodynamic model 
developed in chapter 2. An extended PKPD (i.e. semi-mechanistic) model to describe the 
haemodynamic effects of sodium nitroprusside in adolescents undergoing surgery was 
developed. The model structure was adapted from the minimal haemodynamic model and 
extended based on the postulated drug mechanisms of action and haemodynamic physiologic 
responses reported in the literature. The model was fitted to haemodynamic data and provided 
a good description for MAP and HR changes, based on the individual prediction plots. 
 A mixture KPD model was previously developed by modelling the full range of age of 
individuals participated in the study used in the current analysis (Barrett et al., 2015). However, 
in their work, only MAP measurements were considered when modelling the data, and the 
whole age range for the study population (3 days-17 years old) was included in their analysis 
(203 patients). The model provided good prediction for the data, but could not provide an 
explanation for the two levels of drug sensitivity exhibited by the study participants. This is 
why a mixture model was used with two patient subpopulations having different 𝐶50 estimates. 
In the present work, we tried to implement a mechanistic approach to characterise the 
SNP haemodynamic effects and to provide a deeper insight into the underlying mechanism of 
different drug sensitivities and tachyphylaxis that may emerge upon the administration of SNP. 
The previously developed minimal haemodynamic model was extended by adding a 
state describing the changes in PRA, as guided by the proposed mechanism to explain the 
development of tachyphylaxis in some individuals by increased PRA (Abukhres et al., 1979, 
Amaranath and Kellermeyer, 1976, Bush and Vollmer, 1984, Cottrell et al., 1980, Cottrell et 
al., 1978, Lagerkranser et al., 1985, Miller et al., 1977). Model simulations with and without 
accounting for the possibility of increased PRA upon SNP infusion (see Figure 22)  show how 
accounting for PRA (solid line) adds model flexibility to describe the gradual resistance 
development in some individuals, and the rebound hypertension that can develop upon stopping 
SNP infusion. The individual plots further confirmed this as illustrated in Figure 23, which 
gives an example of the model ability to capture the haemodynamic profile of patients 
developing tachyphylaxis. 
It was noted that the population predictions (PRED) did not provide a sufficient 
description for the data. This can be explained by the fact that the current model does not have 
any covariates as part of the model. This aligns with the previously published analyses on the 
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same study data using either the blinded phase or open-labelled phase, which could not 
correlate any of the investigated factors such as age, baseline MAP, surgery type, and dose 
adjustment frequency or magnitude as an eligible covariate to predict the haemodynamic 
response (Barrett et al., 2015, Spielberg et al., 2014). On the other hand, the individual model 
predictions (IPRED) showed an overall good description for most individual profiles. By 
looking at the eta-shrinkage for the final parameter estimates (see Table 5), none of the values 
exceed 20%, which allows a reasonable diagnosis of the IPRED fitting for the individual data. 
The model could not explain some of the haemodynamic profiles (see Figure 24), where 
an increased MAP was developed upon the infusion of SNP. The mechanistic assumption 
underlying the model is that SNP decreases MAP by inhibiting the TPR and resetting the 
baroreceptor reflex, which contradicts the observed profiles. However, these profiles can be 
explainable if we considered several factors that may affect blood pressure other than SNP 
administration in this study setting. For example, pain, anaesthesia, other administered 
medications, and excitement, which all are known to affect blood pressure; however, these 
factors were not recorded and therefore are not accounted for in the model. 
Although visual predictive check (VPC) is a widely used simulation based tool to 
diagnose model bias with respect to both the fixed and random effects, it was not feasible to 
generate it for our final model. The current study design was based on adaptive dosing, where 
the individual infusion rate is adjusted to the response (i.e. achieving the predefined target 
MAP). In this case generating prediction corrected VPC (pcVPC), is advised where it requires 
implementing the adaptive dosing algorithm when simulating the original dataset (Bergstrand 
et al., 2011). The study protocol stated that in each of the four doing groups, the patients will 
be initiated at one-third the full infusion rate for 5 minutes, then increased to two-thirds the full 
rate for 5 additional minutes, then the dose was increased to the full rate if the target MAP was 
not attained. In addition, termination of the infusion was advised in case of MAP drop below 
the target MAP. However, observing the data records showed inconsistencies in following the 
study protocol for most of the individuals, which makes it hard to implement adaptive dosing 
algorithm to simulate the data and generate a pcVPC. Generated pcVPC without accounting 
for adaptive dosing is provided in Appendix 2 (Section A.2.4)  
The model provided a good description to the data, nevertheless there are some 
limitations related to the study design and the data collection that may not support drawing 
inference to other clinical settings. First, the patients received other medications affecting the 
haemodynamics including anesthetic agents, plasma expanders; however, we cannot backtrack 
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what happened to these patients, and we do not have access to the exact timing for 
administering these medications. Secondly, although the model provided a mechanistic 
description of the tachyphyalxis as explained by increased PRA, it was still not possible to 
provide an explanation for the high variability in PRA, which required implementing a mixture 
model. As compared to the previously published mixture KPD model on the same data (Barrett 
et al., 2015), the final model was not able to further our understanding of why some patients 
show to a higher sensitivity to the drug than the others (i.e. belong to a high 𝐶50, or low a PRA 
subpopulation). Moreover, the current model parameter estimates were assessed based on data 
in adolescents undergoing surgery under anaesthesia, hence they could vary in other settings. 
3.5 Conclusions 
We have developed an extended/semi-mechanistic PKPD model to describe the 
haemodynamic effects of sodium nitroprusside intravenous infusion in adolescents undergoing 
surgery. SNP was shown to exhibit a combined mechanism by inhibiting TPR and resetting 
baroreceptor reflex, with an ultimate hypotensive effect. The model fitted most of the data well 
suggesting its mechanistic plausibility and the flexibility to describe the different response 
patterns elicited by SNP.  
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4.1 Discussion 
The scope of the present thesis was implementing pharmacometric methods in the 
modelling of haemodynamics in humans. We presented a minimal haemodynamic model and 
showed model application to clinical data from the literature on drugs targeting different 
aspects of the cardiovascular system. The model was intended to be used for estimation purpose 
in top-down modelling. The model was developed based on the cardiovascular physiology 
reported in literature and previously published models describing the haemodynamic variables. 
The final model is composed of four states and three parameters and can be used to quantify 
and understand the mechanistic effects of pharmacological agents on the short-term 
haemodynamics of the CVS in humans. 
The minimal model was evaluated using clinical data from the literature for drugs targeting 
HR and total TPR. HR and MAP data from clinical studies on patients who received either 
metoprolol or nifedepine were digitised and superimposed with predictions from the minimal 
model. The results of model evaluation show model flexibility to characterise the different 
haemodynamic profiles at different perturbation sites without data fitting. Moreover, a 
hypothetical scenario of model simulation with and without considering the baroreceptor reflex 
shows that the current closed-loop structure is able to capture the changes in other system’s 
states that may not be the primary perturbation site. Compared to published PKPD models, 
which usually describe the haemodynamic variables separately without accounting for the 
interrelationship between these variables, the current model can accommodate extrapolation to 
situations beyond the range of the data.  
The developed minimal haemodynamic model was applied to clinical data from adolescents 
who received intravenous infusion of SNP during surgery in order to induce hypotension. 
Controlled hypotension is an intraoperative technique used to lower the BP during surgery and 
keep it within a certain predefined window to limit intraoperative blood loss, reduce the need 
for blood transfusions, and improve visualisation of the surgical field. The minimal model was 
extended to accommodate the postulated mechanism of action of SNP in literature.  
The hypotensive effect of SNP has been explained in the literature by being a nitric oxide 
donor having a direct action on vascular smooth muscle inhibiting TPR and causing 
vasodilation (Tinker and Michenfelder, 1976). Some studies postulated the effect of SNP on 
the resetting of the aortic baroreceptors with shifting of the system’s set point toward a lower 
level of MAP (Fritsch et al., 1989, Salgado and Krieger, 1988, Deabreu and Salgado, 1990). 
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The current model application supports a combined mechanism for SNP by inhibiting TPR and 
resetting baroreceptor reflex, with an ultimate hypotensive effect. Several studies have reported 
rapid progressive tolerance development upon infusion of SNP and linked this to increased 
plasma renin activity (PRA) resulting in an opposing vasoconstrictive effect (Heuser et al., 
1985, Cottrell et al., 1980, Amaranath and Kellermeyer, 1976, Cottrell et al., 1978, Khambatta 
et al., 1979, Delaney and Miller, 1980). Tachyphylaxis development was explained in the 
model by the PRA, which was added as a new model state to link the changes in PRA to the 
progressive tolerance that develops in some patients. Due to lack of PK data of SNP, a simple 
one-compartment PK model for SNP and nitric oxide was added to the model, assuming first 
order elimination of SNP and nitric oxide. 
Observed MAP and HR data in these patients were superimposed with predictions from the 
model. The individual model predictions (IPRED) fitted most of the data well, while having 
low shrinkage estimate, suggesting its mechanistic plausibility and the flexibility to describe 
the different response patterns elicited by SNP. However, the population predictions (PRED) 
did not provide a sufficient description for the data which is justified by the lack of covariates 
in the current model. This aligns with the previously published analyses on the same study data 
(including other study phases and age groups in the analysis), which could not correlate any of 
the investigated factors such as age, baseline MAP, surgery type, and dose adjustment 
frequency or magnitude as an eligible covariate to predict the haemodynamic response (Barrett 
et al., 2015, Spielberg et al., 2014).  
Previously, Barrett et al. developed a mixture KPD model for SNP using the data from all 
the age range of the study used in the current analysis (Barrett et al., 2015). The model could 
not provide an explanation for the two levels of drug sensitivity exhibited by the study 
participants. The current model provided a mechanistic description for the development of 
tachyphylaxis by linking increased PRA to tachyphylaxis development. This was explained by 
the relatively slow decline in PRA with a half-life of approximately 30 min (Cottrell et al., 
1980). Nevertheless, due to limitations pertaining to the lack of adequate record for probable 
confounding factors (e.g. administration of other medication affecting haemodynamics, pain, 
and excitement), the model was not able to fully explain the mechanistic underlying of different 
patient sensitivities to SNP. 
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4.2 Limitations and future perspectives 
The proposed model does not account for the circadian variability on the autonomic 
function.  This could be a potential for a future work to expand the utility of the current model 
to situations when the influence circadian variability is evident. On the other hand, the model 
depends on MAP measurements to derive the haemodynamic profiles. Nevertheless, in the 
clinical setting, BP is usually assessed by SBP and DBP rather than MAP, which requires an 
invasive technique to be measured, so MAP is approximately calculated from SBP and DBP 
(Klabunde, 2012). However, at high HR, the formula used to calculate MAP from SBP and 
DBP may not hold anymore because of the change in the length of cardiac cycle and 
distribution between systole and diastole (Moran et al., 1995, Razminia et al., 2004). This limits 
the model application to situations of a significant increase in HR such as in high intensity 
exercise where this relationship may not be constant. 
Furthermore, extending the current minimal model structure to include arterial compliance 
and pulse pressure (PP) will allow SBP and DBP to be modelled separately apart from MAP. 
PP gives a better description of the pulsatile components of BP (i.e. SBP, DBP) compared to 
MAP that describe the static component of BP (i.e. indicates tissue perfusion). PP is highly 
affected by the compliance of blood vessels, hence it provides a better prognostic sensitivity in 
cardiovascular risk stratification and arterial stiffness at older age relative to MAP, which could 
show a slight change, keeping it within the normal range (Selvaraj et al., 2016). Adding these 
components to the model could in turn enhance the model capacity to describe the influence of 
aging and arterial stiffness on haemodynamics. However, this require further clinical data to 
support and evaluate model extension. 
Although the model application supports the possible combined mechanism of SNP (i.e. 
inhibiting TPR, and resetting of baroreceptor), further clinical studies need to be conducted in 
different settings to provide an evidence for this postulation.  On the other hand, the current 
model was evaluated using SNP data in adolescents. The developmental changes in the 
haemodynamic variables (e.g. SV, HR, and TPR) are linked to body size changes and 
physiologic maturation in children and adolescents. This has been described using different 
allometric power functions per each age stratum (Gillum et al., 1982, de Simone et al., 1997, 
Ma et al., 2012, Dewey et al., 2008). Model scaling to other age groups could enhance the 
model application to paediatrics. Further clinical data is needed to evaluate model application 
to paediatrics. 
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4.3 Conclusions 
In conclusion, in the present thesis pharmacometric methods were implemented to develop 
a minimal haemodynamic model and to apply it to clinical data of SNP in adolescents 
undergoing surgery. The minimal model was provided as an open access source through 
GitHub to be used as a generic platform to characterise the short-term haemodynamic changes 
in humans (https://github.com/SalmaBahnasawy/SysModel.git). Model extension to 
mechanistically describe the haemodynamic effects of SNP showed the mechanistic 
plausibility of the proposed model.  
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A.1 Minimal haemodynmic model use for estimation  
Two data sets extracted from literature were used to evaluate the model use for 
estimation purposes. The following points were considered in the current analysis  
1. The extracted data were reported as mean ± SD: 
a. PK (drug plasma concentration) 
b. PD(systolic blood pressure, diastolic blood pressure, heart rate) 
2. For model estimation, only PD data were modelled. PK data were used as 
covariate to link PK to PD using Emax model. This is to minimise the 
variability/error arising from having the summary statistics of the PK to 
propagate to the PD, which is the main scope of the model. 
3. Data sets in the NONMEM format were created using R:  
a. 2 DVs (MAP, HR), with DVID column as a flag  
b. Concentration entries were added in a separate column as a covariate.  
c. The different dose levels were considered as different individuals (e.g. 2 
dosing levels 2 IDs), with BSV allowed on the initial conditions 
(i.e.𝑀𝐴𝑃0, 𝐻𝑅0) 
4. For the nifedipine dataset 
a. PD data are intensely sampled (every 5 minutes for 60 minutes, 13 record) 
while the PK data are more sparsely sampled (6 records over 60min). Linear 
interpolation was implemented to impute the missed PK measurement using 
$FINEDATA utility in NONMEM, and checked the resulting PK profile 
graphically before using the resulting full data set with imputed 
concentrations. 
b. The reported summary PK, PD are not matching in the number of patients 
(for the 10 mg dose: PD is the mean of 11 patients, while PK is the mean of 
7 patients).  
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Results 
i. Model estimates 
a. Metoprolol dataset 
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NONMEM code for estimation of nifedipine dataset 
 
$PROBLEM ESTIMATION OF Nifedipine dataset 
$INPUT ID TIME DOSE=DROP DV DVID CONC CMT 
$DATA Nifefull.csv  
IGNORE=# 
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; Specify drug effect model 
I = (Imax*CONC)/(C50+CONC) ;drug effect on TPR 
 
; set points & MAP 
MAP_SP=MAP0 
SV=A(1)*(1-BET*LOG(A(2)/HR0)) 
MAP = A(2)*A(3)*SV 
DELTA = (MAP-MAP_SP)/MAP_SP    ;change in 
blood pressure 
 
; specify ODEs of differnet cmt 
DADT(1)= KOUT*SV0*(1 - A(4)) -  KOUT*A(1)  ;SV 
DADT(2)= KOUT*HR0*(1 - A(4)) - KOUT*A(2)  ;HR 
DADT(3)= KOUT*TPR0*(1- A(4))*(1-I) - KOUT*A(3) ;TPR with the drug 
effect  
DADT(4)= KOUT*DELTA - KOUT*A(4)   ;delta BR 
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 90 FIX ;SV0 
 (60, 75, 140) ; HR0 
 (90,130,150) ; MAP0 
 (10, 35, 100)  FIX ; KOUT 
 (0, 0.22, 0.9) FIX;BETA 
 (0.01,0.6, 1) ; Imax 
 (20,120,150) ; C50 
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 0.01  ;PPVHR 
 0.01  ;PPVMAP 
 
$SIGMA   
 5 ;ADDMAP 
 5 ;ADDPHR 
 
$EST MAXEVALS=9999 NSIG=3 NOABORT PRINT=20 METHOD=COND 
INTER 
$COV 
$TABLE ID TIME CMT DV DVID PRED IPRED RES CWRES NOAPPEND 
ONEHEADER NOPRINT FILE=sdtab1 
$TABLE ID TIME ETA(1) ETA(2) NOAPPEND ONEHEADER NOPRINT 
FILE=patab1
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A.2.1 MATLAB simulation code for model  
Run file (PD_run.m) 
%% SNP Model simulation w/out PRA  
  
clear all % clears variable cache 
clc  % clears screen 
  




%% Set initial conditions & run simulation 
get_initials 
options = odeset('RelTol',1E-7); 
 
[t, A]= ode15s(@PD_ODEs_PRA,[0 1], A0, options,  K0, K10,  K20, 
V, Imax, IC50, SP_MAP0, SV0,HR0, TPR0, KOUT,k); 
VEC 
Time=t; 
output_PRA=table(Time, SNP,MAP, HR,TPR,SV,PRA); 
  
[t, A]= ode15s(@PD_ODEs_noPRA,[0 1], A0, options,  K0, K10,  
K20, V, Imax, IC50, SP_MAP0, SV0,HR0, TPR0, KOUT,k); 
VEC 
Time=t; 
output_noPRA=table(Time, SNP,MAP, HR,TPR,SV,PRA); 
  




Model Parameters (PD_parameters.m) 
%% PK parameters 
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V=1; 
K0=4000; %infusion rate (ug/hr) 
K10 = 20.8; %hr-1 SN 
K20= 1250; %hr-1 T0.5=2sec 
   




%% Drug parameters 
%DRUG EEFFECT 
 Imax= 1; 
 IC50=3; 
Model Parameters (PD_parameters.m) 
  






A0 = [0 0 SV0 HR0 TPR0 0 0]; 
 
Model ODE with PRA(PD_ODEs_PRA.m) 
 
%% model ode's drug effect with PRA included 
function dAdt = PD_ODEs(t, A, K0, K10,  K20, V, Imax, IC50, 




% Stop the infusion after 1 hour 
if t>=0.5 
   K0=0; 
end 
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%% Specify drug effect 
CP = A(2)/V; 
I1 = (Imax*CP)/(IC50+CP);  
%% Set point  
SP_MAP = SP_MAP0; 
SV=A(3)*(1-0.212*log(A(4)/HR0)); 
MAP = A(5)*A(4)*SV; 
DELTA = (SP_MAP-MAP)/SP_MAP; %change in MAP relative to MAP set 
point 
%% ODEs matrix 
dAdt(1) = K0  - K10*A(1);                   %d(SNP)/dt 
dAdt(2) = K10*A(1) - K20*A(2);             %d(NO)/dt 
dAdt(3)=KOUT* SV0*(1 + A(6)) -  KOUT*A(3);        %d(SV)/dt 
dAdt(4)= KOUT*HR0*(1 + A(6)) - KOUT*A(4);      %d(HR)/dt 
dAdt(5)=KOUT*TPR0*(1-I1)*(1 + A(6))*(1+3*A(7)) - KOUT*A(5); 
%d(TPR)/dt 
dAdt(6)=KOUT*DELTA*(1-I1) - KOUT*A(6);       %d(BR)/dt 




Model ODE w/out PRA(PD_ODEs_noPRA.m) 
 
%% model ode's drug effect  
function dAdt = PD_ODEs(t, A, K0, K10,  K20, V, Imax, IC50, 
SP_MAP0, SV0,HR0, TPR0, KOUT,k) 
  
% Stop the infusion after 1 hour 
if t>=0.5 
   K0=0; 
end 
%% Specify drug effect 
CP = A(2)/V; 
I1 = (Imax*CP)/(IC50+CP); %drug effect on DELTA BAROREFLEX 
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%% Set point  
SP_MAP = SP_MAP0; 
SV=A(3)*(1-0.212*log(A(4)/HR0)); 
MAP = A(5)*A(4)*SV; 
DELTA = (SP_MAP-MAP)/SP_MAP; %change in MAP relative to MAP set 
point 
%% ODEs matrix 
dAdt(1) = K0  - K10*A(1);                       %d(SNP)/dt 
dAdt(2) = K10*A(1) - K20*A(2);                 %d(NO)/dt 
dAdt(3)=KOUT* SV0*(1 + A(6)) -  KOUT*A(3);     %d(SV)/dt 
dAdt(4)= KOUT*HR0*(1 + A(6)) - KOUT*A(4);       %d(HR)/dt 
dAdt(5)=KOUT*TPR0*(1-I1)*(1 + A(6))*(1+3*A(7)) - KOUT*A(5);    
%d(TPR)/dt 
dAdt(6)=KOUT*DELTA*(1-I1) - KOUT*A(6);          %d(BR)/dt 




Save output (VEC.m) 
%% Define variables from algebric equations as vectors 
SNP=A(:,1)/V; 
CP=A(:,2)/V; 
EDRUG = (Imax*CP)./(IC50+CP); 
  
SV=A(:,3).*(1-0.212*log(A(:,4)./HR0)); 
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A.2.2 NONMEM code for SNP model estimation  
;; 1. Based on: run15 
;; 2. Description: run15 Mixture model no bsv 
 
;; x1. Author: Salma Bahnasawy 
 





PHAS ; PHASE OF STUDY 1 = PRE-OPERATIVE, 2 = BLINDED TREATMENT PHASE, 3 = OPEN LABEL 
TREATMENT, 4 = FOLLOW UP 
DPHASE=DROP 
GTX ; RANDOMIZED TREATMENT GROUP MCG/MIN/KG 
TBD ;Time before infusion 
TAD 
DOSE=DROP ; MCG LOCF 
AMT ; MCG 
DURN ; INFUSION DURATION MINUTES 
RATE ; MCG/H 
RINF; Infusion rate at time 
DV ; HR MAP PP SBP DBP 





SEX ; 1=MALE; 2=FEMALE 
AGE 
AGED=DROP 
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WT ; WEIGHT KG 
RACE ; RACE 1 = AMERICAN INDIAN OR ALASKAN NATIVE, 2 = ASIAN, 3 = BLACK OR AFRICAN 
AMERICAN, 4 = NATIVE HAWAIIAN OR PACIFIC ISLANDER, 5 = WHITE OR CAUCASIAN, 6 = OTHER 
ETHN; ETHNICITY 1= HISPANIC; 2 = NON HISPANIC 
L2  




IGNORE (DVID.GT.2)  
IGNORE (ID.EQ.156) 














; simple pk model of NP 
K10= THETA(1) ;elimination rate const of SNP 
K20= THETA(2) ;elimination rate const of NO 
V= THETA(3) 
; PD model 
SV0= THETA(4) 
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; Specify drug effect model 
CP=A(2)/V 
I1 = (Imax*CP)/(IC50+CP) 
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; set points & MAP; 
SV=A(3)*(1-BET*LOG(A(4)/HR0)) 
MAP = A(5)*A(4)*SV 
MAP_SP=MAP0 
DELTA = (MAP-MAP_SP)/MAP_SP   ;change in blood pressure 
 
; specify ODEs of differnet cmt 
DADT(1)= -K10*A(1)       ;SNP 
DADT(2)= K10*A(1) - K20*A(2)      ;NO 
DADT(3)= KOUT*SV0*(1 - A(6)) -  KOUT*A(3)    ;SV 
DADT(4)= KOUT*HR0*(1 - A(6)) - KOUT*A(4)    ;HR 
DADT(5)= KOUT*TPR0*(1-I1)*(1-A(6))*(1-FPRA*A(7)) - KOUT*A(5) ;TPR 
DADT(6)= KOUT*DELTA*(1-I1)- KOUT*A(6)    ;delta BR 
















IF (DVID.EQ.2) THEN 
IPRED=HR 
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(0.001, 20.8) FIX ;K10= THETA(1)  
(0.001, 1250) FIX ;K20= THETA(2)  
(1) FIX ;V= THETA(3)  
(70) FIX ;SV0= THETA(4)  
(60, 85,140) ;HR0= THETA(5)  
(50, 80,120) ;MAP0= THETA(6)  
(0.001, 25) FIX ;KOUT=THETA(8)  
(0.01,1) FIX  ;Imax= THETA(9)  
(0.001, 3) ;C50= THETA(10)  
(0.001, 1.5) FIX ;kpra 
( 0.01)FIX ;FPRA1 
(0.0001, 5) ;FPRA2 
(0, 0.212,1) FIX ;BETA 
(0,0.5,1);P 
$OMEGA BLOCK(2) 
 0.04  ;PPVHR 
 0.01 0.01  ;PPVMAP 
 
$OMEGA BLOCK(2) 
 0.1  ;PPVRUVMAP 






 89.5 ;ADDMAP 
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 5 55.6 ;ADDPHR 
 
$EST MAXEVALS=9999 NSIG=3 NOABORT PRINT=0 METHOD=COND INTER MSFO=msfo16.msf 
$COV 
 
$TABLE ID PHAS TIME MDV CMT RINF MAP_SP DV DVID PRED IPRED SV2 PRA HR RES TARGETMA 
CWRES NOAPPEND ONEHEADER NOPRINT FILE=sdtab16 
$TABLE ID ETA(1) ETA(2) TIME ETHN RACE NOAPPEND ONEHEADER NOPRINT FILE=patab16 
$TABLE ID WT AGE NOAPPEND ONEHEADER NOPRINT FILE=cotab16 
$TABLE ID ETHN RACE NOAPPEND ONEHEADER NOPRINT FILE=catab16 
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A.2.3 Individual plots of the final model  
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